

# HLA-B\*14:02-Restricted Env-Specific CD8+ T-Cell Activity Has Highly Potent Antiviral Efficacy Associated with Immune Control of HIV Infection

Ellen M Leitman, Christian B Willberg, Ming-Han Tsai, Huabiao Chen, Søren Buus, Fabian Chen, Lynn Riddell, David Haas, Jacques Fellay, James J

Goedert, et al.

# ► To cite this version:

Ellen M Leitman, Christian B Willberg, Ming-Han Tsai, Huabiao Chen, Søren Buus, et al.. HLA-B\*14:02-Restricted Env-Specific CD8+ T-Cell Activity Has Highly Potent Antiviral Efficacy Associated with Immune Control of HIV Infection. Journal of Virology, 2017, 91 (22), pp.e00544-17. 10.1128/JVI.00544-17. pasteur-02549962

# HAL Id: pasteur-02549962 https://pasteur.hal.science/pasteur-02549962

Submitted on 21 Apr 2020  $\,$ 

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers. L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



Distributed under a Creative Commons Attribution - NonCommercial 4.0 International License

1	HLA-B*14:02-RESTRICTED ENV-SPECIFIC CD8+ T-CELL ACTIVITY
2	HAS HIGHLY POTENT ANTIVIRAL EFFICACY
3	ASSOCIATED WITH IMMUNE CONTROL OF HIV INFECTION
4	
5	Ellen M Leitman <sup>1,2,#</sup> , Christian B Willberg <sup>3</sup> , Ming-Han Tsai <sup>1</sup> , Huabiao Chen <sup>4,5</sup> , Søren Buus <sup>6</sup> ,
6	Fabian Chen <sup>7</sup> , Lynn Riddell <sup>8</sup> , David Haas <sup>9</sup> , Jacques Fellay <sup>10</sup> , James J Goedert <sup>11</sup> , Alicja
7	Piechocka-Trocha <sup>4</sup> , Bruce D Walker <sup>4,12</sup> , Jeffrey Martin <sup>13</sup> , Steven Deeks <sup>14</sup> , Steven M Wolinsky <sup>3,15</sup> ,
8	Jeremy Martinson <sup>16</sup> , Maureen Martin <sup>17</sup> , Ying Qi <sup>17</sup> , Asier Sáez-Cirión <sup>18</sup> , Otto O Yang <sup>19,20</sup> ,
9	Philippa C Matthews <sup>3,21</sup> , Mary Carrington <sup>4,17</sup> , Philip JR Goulder <sup>1,12</sup>
10	
11 12	<sup>1</sup> Department of Paediatrics, University of Oxford, Oxford, UK
12 13 14	<sup>2</sup> Harvard Medical School, Boston, Massachusetts, USA
14 15 16	<sup>3</sup> Nuffield Department of Medicine, University of Oxford, Oxford, UK
10 17 18	<sup>4</sup> Ragon Institute of MGH, MIT and Harvard, Boston, Massachusetts, USA
19 20 21	<sup>5</sup> Vaccine and Immunotherapy Centre, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA
22 23	<sup>6</sup> Laboratory of Experimental Immunology, Faculty of Health Sciences, University of Copenhagen, Denmark
24 25 26	<sup>7</sup> Department of Sexual Health, Royal Berkshire Hospital, Reading, UK
26 27 28	<sup>8</sup> Integrated Sexual Health Services, Northamptonshire Healthcare NHS Trust, Northampton, UK
29 30	<sup>9</sup> Departments of Medicine, Pharmacology, Pathology, Microbiology and Immunology, Vanderbilt University School of Medicine, Nashville, Tennessee, USA
31 32 33 34	<sup>10</sup> School of Life Sciences, Ecole Polytechnique Fédérale de Lausanne; Swiss Institute of Bioinformatics, Lausanne, Switzerland
35 36 37	<sup>11</sup> Infections and Immunoepidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA
38 39 40	<sup>12</sup> HIV Pathogenesis Programme, The Doris Duke Medical Research Institute, University of KwaZulu-Natal, Durban, South Africa

41 42 43	<sup>13</sup> Department of Medicine, University of California San Francisco Department of Epidemiology and Biostatistics, University of California San Francisco, San Francisco, California, USA
44	<sup>14</sup> Department of Medicine, University of California, San Francisco, California, USA
45 46 47	<sup>15</sup> Division of Infectious Diseases, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA
48 49 50	<sup>16</sup> Department of Infectious Diseases and Microbiology, Graduate School of Public Health, University of Pittsburgh, Pittsburgh, Pennsylvania, USA
51 52 53	<sup>17</sup> Cancer and Inflammation Program, Leidos Biomedical Research, Frederick National Laboratory for Cancer Research, Maryland, USA
54 55	<sup>18</sup> Institut Pasteur, Unité HIV, Inflammation et Persistance, Paris, France
56 57 58	<sup>19</sup> Department of Medicine, Geffen School of Medicine, University of California Los Angeles, Los Angeles, California, USA
59 60	<sup>20</sup> AIDS Healthcare Foundation, Los Angeles, California, USA
61 62 63 64	<sup>21</sup> Department of Infectious Diseases and Microbiology, Oxford University Hospitals NHS Foundation Trust, John Radcliffe Hospital, Oxford, UK
65	#Address correspondence to Ellen M Leitman, ellen_leitman@hms.harvard.edu.
66	
67	Short Title: HLA-B*14:02-Restricted Env-Specific CD8+ T-cells in HIV Control
68	

# 69 **ABSTRACT**

70 Immune control of human immunodeficiency virus type 1 (HIV) infection is typically associated 71 with effective Gag-specific CD8+ T-cell responses. We here focus on HLA-B\*14, that protects 72 against HIV disease progression, but the immunodominant HLA-B\*14-restricted anti-HIV 73 response is Env-specific (ERYLKDQQL, 'HLA-B\*14-EL9'). A subdominant HLA-B\*14-restricted 74 response targets Gag (DRYFKTLRA, 'HLA-B\*14-DA9'). Using HLA-B\*14/peptide-saporin 75 conjugated tetramers, we show that HLA-B\*14-EL9 is substantially more potent at inhibiting viral replication than HLA-B\*14-DA9. HLA-B\*14-EL9 also has significantly higher functional avidity 76 77 (p<0.0001) and drives stronger selection pressure on the virus than HLA-B\*14-DA9. However, 78 these differences were HLA-B\*14 subtype-specific, applying only to HLA-B\*14:02 and not HLA-79 B\*14:01. Furthermore, the HLA-B\*14-associated protection against HIV disease progression is 80 significantly greater for HLA-B\*14:02 than for HLA-B\*14:01, consistent with the superior antiviral 81 efficacy of the HLA-B\*14-EL9 response. Thus, although Gag-specific CD8+ T-cell responses 82 may usually have greater anti-HIV efficacy, factors independent of protein specificity, including 83 functional avidity of individual responses, are also critically important to immune control of HIV. 84

# 86 **IMPORTANCE**

87 In HIV infection, although CTL play a potentially critical role in eradication of viral reservoirs, the 88 features that constitute an effective response remain poorly defined. We focus on HLA-B\*14, 89 unique among HLA associated with control of HIV in that the dominant CTL response is Env-90 specific, not Gag. We demonstrate that Env-specific HLA-B\*14-restricted activity is substantially 91 more efficacious than the subdominant HLA-B\*14-restricted Gag response. Env 92 immunodominance over Gag, and strong Env-mediated selection pressure on HIV, are only 93 observed in subjects expressing HLA-B\*14:02, and not HLA-B\*14:01. This reflects increased 94 functional avidity of Env response over Gag, substantially more marked for HLA-B\*14:02. 95 Finally, we show that HLA-B\*14:02 is significantly more strongly associated with viraemic control 96 than HLA-B\*14:01. These findings indicate that, although Gag-specific CTL may usually have 97 greater anti-HIV efficacy than Env responses, factors independent of protein specificity, including functional avidity, may carry greater weight in mediating effective control of HIV. 98

# 99 INTRODUCTION

100 Spontaneous durable control of HIV is observed in a rare subgroup (<1%) of infected individuals 101 known as 'elite controllers' (1). Non-progressive HIV infection is associated with expression of 102 certain HLA class I molecules (2, 3), such as HLA-B\*57 and HLA-B\*27 alleles (1, 4, 5). An 103 important mechanism underlying the HLA associations with HIV disease outcome is related to 104 the particular HIV-specific epitopes presented by different HLA class I molecules. In particular, 105 'protective' HLA molecules typically present broad Gag-specific epitopes to CD8+ T-cells, 106 whereas disease-susceptible alleles such as HLA-B\*35:01 and HLA-B\*58:02 present Nef- and 107 Env-specific epitopes, respectively, eliciting CD8+ T-cell responses that are typically associated 108 with poor immune control of HIV (6-10). 109 110 Factors contributing to improved immune control in association with broad Gag and not Nef or 111 Env responses include the sequence conservation especially of the capsid protein, because the 112 cost to viral replicative capacity of Gag escape mutants is often significant (11-14). In contrast, 113 Env escape mutants, for example, are typically tolerated by the virus without significant impact 114 on viral replicative capacity (15). In addition, Gag capsid proteins are much more abundant than 115 Env trimers in mature virions (1,000-1,500 per virion versus 10-20, respectively) (16) and Gag 116 epitopes can be presented within two hours of HIV gaining entry into the target cell, prior to de 117 novo HIV protein synthesis (17). Hence, HIV-infected cells can be killed by Gag-specific CD8+ 118 T-cells before new virion production (17, 18). In contrast, Nef- and Env-specific CD8+ T-cell 119 responses kill virus-infected target cells only after de novo synthesis of viral proteins (17-20) and 120 therefore following Nef-mediated HLA class I downregulation (21, 22). Nonetheless, Gag-121 specific CD8+ T-cell responses are not equally efficacious (6, 23, 24), and there is evidence 122 from the SIV/macaque model that certain non-Gag epitopes, for example within Nef and Vif, are 123 important for immune control (25).

124

125 Furthermore, it is clear that several other factors than HIV protein specificity can play an

126 important role in efficacy of an epitope-specific response. These include functional avidity (26,

127 27), polyfunctionality (28), lytic granules (29) and proliferative capacity (30).

128

129 To investigate further the potential role of non-Gag-specific CD8+ T-cell responses in control of 130 HIV infection, we focused here on HLA-B\*14, where the dominant HIV-specific CD8+ T-cell 131 response is in Env (31, 32). The association between HLA- B\*14 and immune control of HIV has 132 not been well-studied to date (33), since most studies of elite controllers have focused on those 133 expressing HLA-B\*27 or B\*57 (26, 29, 30, 34-38). Although HLA-B\*14 is not as strongly 134 associated with HIV disease progression as HLA-B\*27 or HLA-B\*57, nonetheless large studies 135 have consistently shown a significant protective effect (3, 39-41). In addition to the dominant 136 Env-specific CD8+ T-cell response, HLA-B\*14-positive individuals also make a subdominant 137 Gag-specific CD8+ T-cell response (42). We set out to investigate the role of these two 138 specificities in HLA-B\*14-mediated suppression of HIV and to understand the mechanisms 139 underlying the observed differential antiviral activity among HLA-B\*14-restricted CD8+ T-cell 140 specificities.

141

# 142 MATERIALS AND METHODS

# 143 Study subjects

Adult chronically HIV-infected ART-naïve subjects studied here were enrolled in the following cohorts: (i) Thames Valley cohort, UK (n=30) (18); (ii) Gateway cohort, Durban, South Africa (n=17) (43); (iii) the SCOPE (Study of the Consequences of Protease Inhibitor Era) cohort, San Francisco, USA (n=2) (44). Subjects from all cohorts provided written informed consent and the study was approved by the institutional boards of the University of Oxford, the University of KwaZulu-Natal and the University of California, San Francisco. HLA typing was performed using a locus specific PCR amplification strategy and a heterozygous DNA sequencing methodology for the HLA class I exon 2 and 3 amplicons. HIV plasma viral load measurements were done
using the Roche Amplicor version 1.5 assay with COBAS Amplicor (Thames Valley, Gateway
and SCOPE cohorts) or using the Abbott RealTime HIV assay (SCOPE cohort). CD4+ T-cell
counts were enumerated by flow cytometry using standard clinical protocol. Median viral load of
these study subjects was 9,700 copies/ml (IQR 555-31,500); median CD4+ T-cell count was 527
cells/mm<sup>3</sup> (IQR 420-711).

157

To analyse the associations between the expression of HLA-B\*14:01 and HLA-B\*14:02 with immune control of HIV, viral load and HLA data of the ART-naïve chronically HIV-infected subjects (n=5,004; Caucasians: n=3,259; African Americans: n=1,745) were used. These subjects were from the cohorts from the following studies:

- AIDS Clinical Trial Group (ACTG) Study (<u>https://actgnetwork.org</u>);
- International HIV Controllers Study (3) (<u>http://www.hivcontrollers.org</u>);
- Multicenter AIDS Cohort Study (MACS) (45) (<u>https://statepi.jhsph.edu/macs/macs.html</u>);
- Multicenter Hemophilia Cohort Study (MHCS) (46)
- 166 (<u>https://biolincc.nhibi.hih.gov/studies/mhcs</u>);
- The Study of the Consequences of Protease Inhibitor Era (SCOPE) (47)
- 168 (<u>https://hiv.ucsf.edu/research/scope.html</u>);
- Swiss HIV Cohort Study (48) (<u>www.shcs.ch</u>).

170 Viraemic controllers were defined as individuals with viral load <2,000 copies/ml; non-controllers

171 were defined as individuals with viral loads >10,000 copies/ml.

172

# 173 Tetramer generation and staining

- 174 Peptide-MHC tetramers conjugated to fluorophores were generated as previously described,
- using streptavidin-PE or APC (49). Cytotoxic saporin-conjugated tetramers were produced by

176 the same method using streptavidin-SAP (Advanced Targeting Systems) to tetramerise peptide-177 MHC monomers according to the published approach (50). Briefly, these modified tetramers are 178 coupled to a toxin, ribosome-inactivating protein saporin (SAP), that can selectively kill antigen-179 specific cells of interest and thereby evaluate the contribution of a particular CD8+ T-cell 180 specificity to viral inhibition (50-54). Efficiency of tetramerisation was confirmed by staining with 181 anti-mouse Ig κ beads (BD Biosciences) with an anti-HLA antibody, followed by tetramer 182 staining. For staining with the fluorescently-conjugated tetramers, PBMC or expanded CD8+ T-183 cells (0.5-1x10<sup>6</sup> cells per stain) were washed with PBS, incubated with relevant tetramers for 20-184 30 minutes at room temperature in a 96 U-bottom plate, washed again, further incubated with 185 fluorochrome-conjugated antibodies for 15 minutes at room temperature and fixed in 2% 186 formaldehyde solution at 4°C. For staining with SAP-conjugated tetramers, cells were incubated 187 with tetramers for 30 minutes at room temperature, washed, fixed and permeabilised with BD 188 Cytofix/Cytoperm kit (BD Biosciences) and then incubated with a secondary anti-SAP antibody 189 (Alexa Fluor 488, Advanced Targeting Systems) as previously published (50). Controls included 190 cells incubated with no tetramer, HLA-mismatched SAP-conjugated tetramers and free 191 unconjugated SAP. All samples were acquired within 6 hours of staining on MACSQuant 192 Analyser 10 (Miltenyi Biotec). Negative gates were set up using staining with no tetramer or with 193 HLA-mismatched tetramers. Samples were analysed in FlowJo version 9.7.6 (Tree Star, Inc.) 194 and hierarchically gated on singlets, lymphocytes, live cells and CD3+CD4- cells around CD8+ 195 tetramer-specific cell populations; in viral inhibition assays, cells were gated on live CD4+GFP+ 196 populations.

197

# 198 Selective depletion of antigen-specific CD8+ T-cells using cytotoxic tetramers

199 Antigen-specific CD8+ T-cells were selectively depleted using cytotoxic saporin-conjugated

- 200 tetramers (tet-SAP) as described previously and confirmed in our laboratory (50). First, CD8+ T-
- 201 cells within PBMC were expanded using a monoclonal CD3.4 antibody bi-specific for CD3 and

202 CD4 (the NIH AIDS Reagent Program) which simultaneously eliminates CD4+ T-cells and 203 expands CD8+ T-cells (55-57). Expanded CD8+ T-cells were cultured in R10 medium (RPMI, 204 10% fetal calf serum (Sigma), 1% L-glutamine (Sigma) and 1% penicillin-streptomycin (Sigma)), 205 supplemented with 50 U/ml human premium grade IL2 (Miltenyi Biotec) (R10/50) for 10-14 days 206 to achieve >90% purity. Expanded CD8+ T-cells were then treated with tet-SAP (5-10 nM) for 2 207 hours at 37°C, washed three times with R10 and cultured in R10/50 for 24-48 hours before using 208 them as effector cells in viral inhibition assays (see below). Control treatments included HLA-209 mismatched tet-SAP, free saporin or no treatment. Depletion efficiency was confirmed by 210 tetramer staining prior to viral inhibition assay set-up. Tet-SAP-mediated depletion was pre-211 validated by depleting antigen-specific cells using PE-conjugated tetramers and anti-PE 212 magnetic beads (StemCell Technologies).

213

# 214 Generation of polyclonal epitope-specific CD8+ T-cell lines

215 Epitope-specific CTL lines were generated as previously described (18) with modifications. 216 Briefly, fresh PBMC were peptide-pulsed (2-3x10<sup>6</sup> PBMC/peptide at 200 µg/ml final 217 concentration) for 1 hour and fed with fresh R10/50 2-3 days for 14-21 days. Specificity was 218 tested by tetramer staining. To remove non-specific cells, tetramer-positive cells were sorted on 219 MoFlo XDP (Beckman Coulter) and expanded in R10/50 supplemented with monoclonal OKT3 220 antibody (eBioscience) at 0.1 µg/ml. At the time of the initial set-up and every 10-14 days after, 221 peptide-pulsed irradiated HLA-matched B cells and irradiated feeder PBMC from three HIV-222 negative donors were added to the sorted cells at a 1:1:1 ratio. Specificity and purity of 223 expanded CD8+ T-cells was confirmed by tetramer staining immediately before using them as 224 effector cells in viral inhibition assays.

225

# 226 Generation of CD8+ T-cell clones

227 Epitope-specific clones were generated as previously described (38). Briefly, PBMC were 228 stained with fluorescently labeled tetramers. Tetramer-specific single cells were sorted on MoFlo 229 XDP (Beckman Coulter) directly into U-bottom 96-well plates (single cell/well) in R10/50 230 containing monoclonal OKT3 antibody (eBioscience) at 0.1 µg/ml. Twice a week half of the 231 media was replaced with fresh R10/50. After 2-3 weeks, cells were tested for their specificity by 232 tetramer staining. Epitope-specific clones were transferred to 48-well and then to 24-well plates; 233 at the time of transfer and/or every 14-21 days, clones were restimulated with monoclonal OKT3, 234 peptide-pulsed irradiated HLA-matched B cells and irradiated feeder PBMC from three HIV-235 negative donors.

236

## 237 Viral inhibition assays

238 To evaluate anti-HIV suppressive capacity of ex vivo unstimulated CD8+ T-cells or stimulated 239 epitope-specific CD8+ T-cells, we modified previously described viral inhibition assay (58). We 240 used an HIV-permissive T1 cell line untransfected or transfected with HLA-B\*14:02 gene 241 (provided by Otto Yang; this cell line also expresses HLA-A\*02, HLA-B\*05, HLA-B\*06) (59) as 242 target cells. Effector cells were: (i) 'zapped' CD8+ T-cells, from which Env-EL9- or Gag-DA9-243 specific cells were selectively depleted using tet-SAP as described above; (ii) CTL lines; and (iii) 244 CD8+ T-cell clones. For the initial setup, target cells were infected with pre-titrated NL4-3-GFP 245 by spinoculation for 1 hour, incubated at 37°C for 1 hour, repeatedly washed and further cultured 246 with or without effector cells in duplicate or triplicate. Every 2-3 days, cultures were fed and 247 stained to assess live CD4+ GFP+ cells. % GFP+ uninfected target cells served as a 248 background, subtracted from all values. HIV-suppressive capacity was calculated at the time of 249 the peak of viral growth as follows (58): suppressive capacity =  $log_{10}$ (%GFP+ infected target 250 cells without effector cells / %GFP+ target cells with effector cells).

251

The viral inhibition assays shown were done using CTL lines and clones that were generatedfrom 3 subjects.

254

# 255 Antibodies

256 Antibodies used: αCD3-Brilliant Violet 421 (UCHT1), αCD4-APC (OKT4), αCD4-FITC (OKT4)

257 and αCD8-PE/Cy7 (RPA-T8) (BioLegend); αHLA-APC (G46-2.6) (BD Biosciences); and LIVE-

DEAD fixable near-IR marker (Life Technologies); polyclonal chicken αSaporin-Alexa Fluor 488
 (Advanced Targeting Systems).

260

# 261 Interferon-γ ELISPOT assays

262 Freshly isolated or cryopreserved PBMC were screened in interferon-γ ELISPOT assays to

263 quantify CD8+ T-cell responses to a set of 410 overlapping 18-mer peptides spanning the HIV-

264 proteome (6) and HLA-restricted optimal epitopes listed in the Los Alamos A-list of optimal HIV

265 CTL epitopes (60). ELISPOT assays were performed as previously described (61, 62). Spots

266 were counted using an automated ELISPOT reader (AID ELISPOT v4.0, Autoimmun

267 Diagnostika, Germany). Positive responses had to be at least three times the mean number of

spot-forming colonies (SFC) in the four control wells and >50 SFC/million PBMC after

269 background subtraction. HIV peptides were produced by Schafer-N.

270

# 271 Measurement of functional avidity

Functional avidity, or antigen sensitivity, was defined as the concentration of an exogenous
peptide required to elicit half-maximal cellular response. Functional avidity of CD8+ T-cells within
PBMC was assessed in *ex vivo* interferon-γ ELISPOT assays by incubating 10<sup>5</sup> PBMC per well
with serial peptide dilutions over a range of seven log<sub>10</sub> units in triplicate. The peptides used
were wildtype Gag-DA9 and Env-EL9. ELISPOT assays were performed as described above.

# 278 Site-directed mutagenesis of NL4-3

279 Y301F, K302R, and Y301F/K302R mutations of HIV Gag sequence as well as K588Q and 280 K588R mutations in Env sequence were introduced respectively into the HIV subtype B NL4-3 281 plasmid by using QuikChange Lightning site-directed mutagenesis kit (Agilent technologies) 282 along with custom-designed mutagenesis forward and reversed primers. The forward primers 283 are shown as follows (mutated codons shown in bold): 5'-C CTG GCT GTG GAA AGA TAC CTA 284 CAG GAT CAA CAG CT-3' (Env K588Q); 5'-GAC TAT GTA GAC CGA TTC TTT AAA ACT CTA 285 AGA GCC GAG-3' (Gag Y301F); 5'-T AGA GAC TAT GTA GAC CGA TTC TAT AGA ACT CTA 286 AGA GCC G-3' (Gag K302R); 5'-A GAC TAT GTA GAC CGA TTC TTT AGA ACT CTA AGA 287 GCC GAG CAA G-3' (Gag Y301F/K302R). All mutations were confirmed by sequencing.

288

# 289 Virus production and replication kinetics

290 All plasmids were maxipreped according to manufacturer's instruction (HiSpeed® plasmid Maxi 291 Kit, Qiagen, Hilden, Germany). To generate mutant viruses, the mutated NL4-3 Gag-Pro 292 amplified purified PCR products with the BstE II (New England Biolabs, Ipswich, MA) linearized 293 pNL4-3Δgag-protease were transfected into GFP reporter GXR cells via electroporation in a 294 BioRad GenePulsar II using 0.4 cm cuvettes at 300 Volts, 500µF, and infinite resistance (14). 295 Virus propagation was then monitored by flow cytometry (LSRII, BD Biosciences) to detect GFP-296 expressing infected cells for two weeks in culture with GXR cells. Virus culture supernatants 297 were harvested when 30% cells were GFP-positive. Viruses were aliquoted and stored at -80°C 298 until use. All mutations were confirmed again by extracting viral RNA from the harvested 299 supernatant and sequencing. Nucleotide similarity reached 99.99%. Along with WT as positive 300 controls and two negative controls without viruses, NL4-3 mutant viruses were incubated with 301 GXR cells in a 24-well plate for determination of viral titres, as previously described (63). A low 302 MOI (0.01%) was set as the lowest threshold for determining the amount of virus required for 303 inoculation. The GFP+ expression was measured by flow cytometry from day 2 to 7 before it

reached the saturated 30-40%. The viral replication capacity was defined by the semi-log
calculation of the mean slope of exponential growth in Excel. This was further calibrated to the
normalised value relative to the wild type NL4-3 respectively. All assays were done at least in
triplicate.

308

# 309 Amplification and sequencing of proviral DNA

310 Genomic DNA was extracted from whole blood QIAmp reagents (QIAGEN, UK), following

311 manufacturer's protocol. For the subjects from the SCOPE cohort whole blood was unavailable

312 and DNA was extracted from cryopreserved PBMC using QIAmp DNA Mini Kit following

313 manufacturer's protocol (QIAGEN). HIV Gag and partial Env (containing HLA-B\*14-Env-EL9

314 <sup>584</sup>ERYLKDQQL<sup>592</sup> epitope) segments were amplified by nested PCR, as previously described

315 (64), using: Gag-specific primers 5'-CTCTAGCAGTGGCGCCCGAA-3', 5'-

316 TCCTTTCCACATTTCCAACAGCC-3' for the first round (product size 1,418 base pairs; HXB2

317 coordinates 627-2045) and 5'-ACTCGGCTTGCTGAAGTGC-3', 5'-

318 CAATTTCTGGCTATGTGCCC-3' for the second round (product size 1307 base pairs; HXB2

319 coordinates 696-2003); Env-specific primers 5'-GGAGATATAAGACAAGCACATTG-3', 5'-

320 CCCTGTCTTATTCTTCTAGGT-3' for the first round (product size 1579 base pairs; HXB2

321 coordinates 7194-8773) and 5'-GTGGAGGAGAATTTTTCTATTG-3', 5'-

322 CTATCTGTTCCTTCAGCTACTGC-3' for the second round (product size 1349 base pairs; HXB2

323 coordinates 7357-8707). PCR products were purified using QIAquick PCR Purification Kit

324 (QIAGEN, UK) according to the manufacturer's instructions. All sequencing was done using

325 BigDye Terminator v3.1 Ready Reaction mix (Applied Biosystems) as previously described (64)

326 and analysed using Sequencher v4.8 (Gene Codes Corp.). We generated maximum-likelihood

327 trees of all sequences, using Mega6.06-mac software and FigTree v1.4.2, to exclude the

328 possibility of contamination with laboratory viral strains. HIV subtypes were further confirmed

with NCBI (website) and REGA (website) HIV genotyping tools. GenBank accession numbers
 MF445302-MF445379.

331

# 332 Statistical analysis

333 Statistical analyses were performed in GraphPad Prism for Mac OSX, 5.0c (GraphPad 334 Software). We used paired t-test to compare differences between remaining infected target cells 335 without effector cells to those with effector cells at the peak of viral replication; Kruskal-Wallis 336 test with Dunn's post-test (for >2-group analysis) or Mann-Whitney U test (for 2-group analysis) 337 to analyse differences in HIV suppressive capacity; Fisher's Exact Test to analyse differences in 338 recognition of Env-EL9 versus Gag-DA9 epitopes and in autologous sequences of Env-EL9 339 versus Gag-DA9 epitope; Mann-Whitney U test for differences in magnitude and functional 340 avidity of Env-EL9 versus Gag-DA9 CD8+ T-cell responses, in frequency of tetramer-specific 341 cells in HLA-B\*14:01- versus HLA-B\*14:02-positive subjects and in viral load and CD4+ T-cell 342 counts; Spearman correlation to analyse the correlation between response magnitude and 343 functional avidity; ANOVA with Dunnett's Multiple Comparison Test for differences in viral 344 replicative capacity of different viral constructs. Functional avidity (EC50) was calculated in 345 Prism using a dose-response function.

346

To analyse associations between HLA class I expression and HIV immune control, SAS 9.2 (SAS Institute) was used. Genotype frequencies on individual HLA-B alleles were computed using PROC FREQ. To calculate OR and 95% CI for viraemic controllers versus non-controllers with adjusting by HLA-B\*27 and HLA-B\*57 PROC LOGISTIC was used; OR<1 indicates protection. Presence versus absence of all individual HLA-B alleles that have a frequency equal to or greater than HLA-B\*14:01 were included in the models with stepwise selection.

353

#### 354 **RESULTS**

#### 355 Higher antiviral potency of B\*14:02-Env-EL9 versus -Gag-DA9 CD8+ T-cell response

356 The starting point for this study was an 'elite controller' subject, Subject-1, who first tested HIV-

357 positive in UK in 2011, having previously had two negative tests in 2005 and 2008 (Fig 1A).

358 Since the positive HIV test, Subject-1 maintained an undetectable viral load (<40 copies/ml) and

359 healthy and stable CD4+ T-cell counts (median 1,555 cells/mm<sup>3</sup>, IQR 1,345-1,788). Viral

360 sequencing revealed that she was infected with subtype B virus. HLA genotyping showed that

361 she was HLA-B\*14:02/HLA-C\*08:02 homozygous and also expressed another HLA molecule,

362 HLA-A\*74:01, associated with slow disease progression (65).

363

364 To investigate the role HLA-B\*14:02-restricted CD8+ T-cell responses might play in immune

365 control of HIV, we first screened PBMC in this individual for HIV-specific IFN-y ELISPOT

366 responses using overlapping peptides spanning the entire HIV proteome (39) together with

367 previously defined HIV-specific epitopes (66). The HLA-B\*14:02-restricted responses dominated

368 overall, the highest magnitude responses being to the HLA-B\*14:02-restricted Env-EL9

(<sup>584</sup>ERYLKDQQL<sup>592</sup>) (31) and its corresponding overlapping peptide Env-366 369

(<sup>579</sup>RVLAIERYLKDQQLLGIW<sup>596</sup>) (Figs 1B,C). The next highest optimal peptide response was 370

371 towards the HLA-B\*14:02-Gag-DA9 epitope (<sup>298</sup>DRFYKTLRA<sup>306</sup>) (42).

372

373 To test the hypothesis that suppression of HIV in this patient was mediated principally by HLA-374 B\*14:02-restricted CD8+ T-cell activity, we next compared the antiviral potency of Env-EL9- and 375 Gag-DA9-specific CD8+ T-cells. From this same elite controller ('Subject-1') bulk CD8+ T-cells 376 were first expanded with the bi-specific CD3.4 antibody (55-57), and then depleted of selected 377 CD8+ T-cell specificities using cytotoxic saporin-conjugated tetramers (see Methods) (Fig 1D). 378 The ability of the bulk or depleted CTL to inhibit viral replication in vitro was then evaluated using 379 T1 cells expressing HLA-B\*14:02 as CD4+ T-cell targets and the B clade NL4-3 as the test 380

strain of HIV (Figs 1E,F). Removal of the Env-EL9 specificity substantially reduced the HIV-

suppressive capacity of the expanded CD8+ T-cells (22% of target cells infected versus 0.001%
(Fig 1E); and suppressive capacity was reduced by 26-fold (bulk CD8: 3.85 log<sub>10</sub> versus EnvEL9-depleted CD8: 0.15 log<sub>10</sub>) (Kruskal-Wallis p=0.02; Fig 1F). In contrast, depletion of GagDA9-depleted cells made little impact. This result suggests that the presence of Env-EL9
specificity represents the majority of CD8+ T-cell-mediated control of viral suppression in
Subject-1, and that the Gag-DA9 specificity does not contribute significantly.

387

388 A potential caveat of this finding in this study subject is the unequal frequency of Env- and Gag-389 specific CD8+ T-cells, with Env-specific cells being nearly 20-fold more frequent than Gag-390 specific cells (Fig 1D). To address this matter, we adopted two approaches. First, we repeated 391 targeted depletion experiments using cells from another chronically B-clade infected HLA-392 B\*14:02-positive controller (Subject-2, VL=80 copies/ml, CD4=1,355 cells/mm<sup>3</sup>), who had equal 393 frequencies of Env-EL9- and Gag-DA9-specific CD8+ T-cells (Fig 1G, left panels). As with 394 Subject-1, elimination of the Env-EL9 specificity resulted in preservation of 25% of infected 395 target cells at the peak of viral replication compared to only 1% in bulk CD8+ T-cell coculture 396 (Fig 1H), representing a 16-fold reduction (1.6  $\log_{10}$  versus 0.1  $\log_{10}$ ) of suppressive capacity of 397 the Env-EL9-depleted CTL (Kruskal-Wallis p=0.03; Fig 1I). In contrast, Gag-DA9 depletion had 398 only a minor effect, thus supporting the notion that Env-EL9-specific CTL mediate the major 399 antiviral efficacy of the two HLA-B\*14:02-restricted responses.

400

In the second approach, we tested antiviral efficacy of Env-EL9- and Gag-DA9-specific CD8+ Tcells directly by generating epitope-specific CTL lines and clones. In the experiments using peptide-specific lines (Figs 2A-C), once again Env-EL9-specific CTL were significantly more potent at suppressing viral replication at the same effector to target ratio 1:100 (p=0.02; Figs 2B,C). Similarly, Env-EL9-specific CTL clones were more potent inhibitors of viral replication than were Gag-DA9 clones. This was particularly evident at the lower effector to target ratios

407 (1:1000) (Figs 2D-F). Taken together, these experiments suggest that Env-EL9-specific CD8+ T 408 cells are more efficacious at suppressing HIV replication than Gag-DA9-specific cells.

409

# 410 Higher functional avidity, antigen recognition, and magnitude of EL9 versus DA9

411 In order to further investigate this observed antiviral superiority of Env-EL9-specific cells over 412 Gag-DA9-specific cells, we next examined functional avidity of the two specificities (determined 413 by the peptide concentration required for 50% maximal recognition or EC50), response 414 magnitude and frequency of epitope recognition in a larger number of HLA-B\*14-positive 415 subjects (n=30). Among all HLA-B\*14-positive subjects, functional avidity, or antigen sensitivity 416 (EC50), of the Env-EL9 response was >24-fold higher than that of the Gag-DA9 response 417 (median 0.84 versus 20.3 µM, p<0.0001; Fig 3A, left panel). This difference was significant 418 among both HLA-B\*14:01-positive (median 3.7 versus 21.3 µM, p=0.003) and HLA-B\*14:02-419 positive subjects (median 0.3 versus 19.8 µM, p<0.0001; Fig 3A, right panel). However, Env-EL9 420 functional avidity was 12-fold higher in HLA-B\*14:02-positive subjects than in HLA-B\*14:01-421 positive subjects (p=0.005; Fig 3A, right panel).

422

423 The magnitude of the Env-EL9 response was also >9-fold higher than that of the Gag-DA9 424 response among all HLA-B\*14-expressing subjects among responders (p=0.003; Fig 3B, left 425 panel). This difference was only significant among HLA-B\*14:02-positive subjects (Fig 3B, right 426 panel). Additionally, HLA-B\*14:02-positive subjects had a significantly higher magnitude of the 427 Env-EL9 response compared to the HLA-B\*14:01-positive subjects (p=0.03). Interestingly, the 428 magnitude of both Env-EL9 and Gag-DA9 responses was negatively correlated with EC50 (i.e. 429 positively with functional avidity) (Env-EL9: r=-0.73, p=0.0002; Gag-DA9: r=-0.88, p<0.0001; Fig 430 3C), indicating that cells with higher functional avidity mounted a response of greater magnitude. 431

Together, these data demonstrate that the greater antiviral potency of the HLA-B\*14-Env-EL9specific response observed above is also associated with higher functional avidity and response
magnitude compared with the Gag-DA9-specific response.

435

## 436 Differential Env-EL9 and Gag-DA9 selection pressure in B\*14:01 versus B\*14:02

437 To further understand the differences between Env-EL9- and Gag-DA9-specific CD8+ T-cell 438 function, we next investigated what selection pressure is imposed on the virus by these two 439 responses (Fig 4). Consistent with previously published data describing HLA-associated 440 polymorphisms from analysis of 3,754 HLA-typed treatment-naïve persons (67, 68) within the 441 Env-EL9 epitope (Fig 4A), K588Q is strongly selected among both HLA-B\*14:01- and HLA-442 B\*14:02-positive persons, and variants at Env-588 and at other residues within Env-EL9 are 443 observed more commonly in HLA-B\*14:02-positive subjects (although here these differences 444 between HLA-B\*14:01- and HLA-B\*14:02 did not reach statistical significance; Fig 4B). These 445 Env-EL9 sequence data indicate stronger selection pressure imposed on the virus by the HLA-446 B\*14:02-EL9 response than by the HLA-B\*14:01-restricted EL9 response.

447

448 To put these Env-EL9 variants arising in HLA-B\*14-expressing individuals into the context of 449 variation within this epitope overall, the frequency of Env-EL9 variants in B- and C-clade 450 infection in all subjects (https://www.hiv.lanl.gov) is 50% and 34%, respectively, the most 451 frequent variants being K558R (29% and 9% in B- and C-clade sequences, respectively), 452 K588Q (8% and 16%). Thus, K588R is relatively common, and, as shown in Fig 4A, is not an 453 HLA-B\*14:01 or HLA-B\*14:02 footprint, and indeed is not selected without accompanying 454 variants in any of the subjects studied here; whereas K588Q is selected in 17/35 (49%) HLA-455 B\*14+ve subjects studied here, and in 17/25 (68%) of those whose autologous virus encoded 456 Env-EL9 variants.

457

60	K202D verient is only collected in LILA D*14:01 positive subjects (n. 0.01). Thus there was
	K302R variant is only selected in HLA-B*14:01-positive subjects (p=0.01). Thus there was
61	significantly more variation in HLA-B*14:02-positive subjects in the Env-EL9 epitope than in
62	Gag-DA9 (p=0.001; Fig 4B), consistent with this being the dominant response among HLA-
63	B*14:02-positive subjects. Among B*14:01-positive subjects the Env-EL9 epitope was not
64	targeted significantly more than the Gag-DA9, and correspondingly there was no significant
65	difference in the selection of variants within Env-EL9 and Gag-DA9 in these subjects.
66	
67	Selection of K588Q and not K588R is an escape variant in HLA-B*14-positive subjects
68	The Env-EL9 sequence data shown above confirm previous studes showing that K588Q at
69	position 5 (P5) in the epitope and binding in the D pocket of the HLA-B*14 peptide-binding
70	groove (70) is an HLA-B*14 footprint but K588R is not (67). This is surprising, given the relatively
71	frequent occurrence of Arg/Lys substitutions as a mechanism by which HIV can escape
72	recognition by other CTL specificities. Indeed, the HLA-B*14:01-associated escape variant
73	within Gag-DA9 is a case in point, K302R being the substitution characteristically selected at P5
74	in the epitope.
75	
76	In order to address this question, the ability of Env-EL9-specific CD8+ T-cells to cross-react with
77	the K588Q and with the K588R variants were analysed in 8 HLA-B*14-positive subjects for
78	whom samples were available. In 6 of 8 subjects the autologous variant was K588Q, and in the
79	remaining two autologous virus encoded wildtype Env-EL9. The pattern of cross-recognition
80	observed was quite distinct for the two varants K588Q and K558R. For K588Q, in all 8 subjects,
81	the frequency of cross-reactive cells, double-stained by EL9-wt and EL9-K558Q tetramers, was
82	substantially lower than the frequency of EL9-wt-specific CD8+ T-cells (Fig 5). In all cases,
83	including the 6 in whom the K588Q variant had been selected, EL9-wt-specific responses were
	<ul> <li>63</li> <li>64</li> <li>65</li> <li>66</li> <li>67</li> <li>68</li> <li>69</li> <li>70</li> <li>71</li> <li>72</li> <li>73</li> <li>74</li> <li>75</li> <li>76</li> <li>77</li> <li>78</li> <li>79</li> <li>80</li> <li>81</li> <li>82</li> </ul>

For the Gag-DA9 epitope, as shown in previous large cohort studies (67-69), the most frequent

readily detectable, and in 5 of 8 cases greater in magnitude than the EL9-K588Q-specific
response. By contrast, in most of these subjects (6 of 8), the frequency of CTL cross-reactive for
EL9-wt and K588R was higher than that of EL9-wt-specific CTL. Indeed, in 6 of 8 of these
subjects the K588R variant-specific response was higher than the EL9-wt-specific response.

These results would explain why K588R is not selected as an escape mutant, since the EL9-wtspecific response typically cross-reacts strongly with the K588R variant. By contrast, the K588Q variant is not cross-recognised and therefore this mutant woulkd carry a selective advantage for the virus.

493

# 494 Impact of Gag-DA9 and Env-EL9 escape mutants on viral fitness and HIV outcome

495 Previous studies have indicated that the most effective CTL responses are those capable of 496 driving the selection of escape mutants that significantly reduce viral replicative capacity (11-14). 497 These are more likely in p24 Gag, which is highly conserved as opposed to Env, which is highly 498 variable. We next, therefore, investigated the impact on viral replicative capacity of the most 499 common escape mutants in p24 Gag-DA9 and Env-EL9 (Figs 6A,B). In contrast to the general 500 observation of the high cost of p24 Gag mutants, the K302R mutant had little impact on viral 501 replicative capacity (VRC), consistent with previous studies of this variant (71). The Env EL9 502 mutant marginally but not significantly decreased VRC. Thus, in this particular case, the fitness 503 cost resulting from the selection of escape mutants within the capsid protein appears to have 504 little impact on viral replicative capacity.

505

HLA-B\*14-positive subjects who had wild type Env-EL9 had lower viral loads (median 9,068
versus 21,546 copies/ml, p=0.05; Fig 6C) and higher CD4+ T-cell counts (median 606 versus
455 cells/mm<sup>3</sup>, p=0.005). Again, this difference was exclusive to HLA-B\*14:02-positive subjects
among whom individuals with wild type Env-EL9 had lower VL versus those with a variant

(median 80 versus 20,003 copies/ml, p=0.04; Figs 6D,E), and a trend towards higher CD4+ Tcell counts (median 1,340 versus 410 cells/mm<sup>3</sup>, p=0.2), although there were only three subjects
with wild type sequence.

513

514 Taken together these results suggest that the Env-EL9 response is highly effective and 515 contributes to successful immune control of HIV, whereas Gag-DA9 is not.

516

# 517 Stronger association of HLA-B\*14:02 than HLA-B\*14:01 with HIV immune control

518 On the basis of the findings above, if the B\*14-Env-EL9 response makes a significant 519 contribution to immune control of HIV, one would predict greater protection against HIV disease 520 progression in association with HLA-B\*14:02 compared with HLA-B\*14:01. To test this 521 hypothesis, we first compared the frequency of HLA-B\*14:01 with that of HLA-B\*14:02 in 522 viraemic controllers (viral load <2.000 copies/ml) versus non-controllers (viral load>10.000 523 copies/ml) derived from several previously well-described cohorts (see Methods). Although there 524 was a trend towards HLA-B\*14:02 being more protective than HLA-B\*14:01 among HLA-B\*14-525 positive Caucasians (self identified as 'white'; n=285) and HLA-B\*14-positive African Americans 526 (self-identified as 'black'; n=104), in neither group was the difference statistically significant 527 (Table 1). We then extended the analysis to all controllers and non-controllers in our cohorts 528 (whites, n=3,259; blacks, n=1,745) by performing a regression analysis with stepwise selection 529 that included all HLA-B alleles having a frequency equal to or greater than HLA-B\*14:01 (HLA-B\*14:01 frequency in whites: 2.42%; in blacks: 1.60%) (Table 2). HLA-B\*14:02 showed a 530 531 significant independent protective effect in both whites (OR = 0.44, p = 2e-7 in whites) and 532 blacks (OR = 0.54, p = 2e-2 in blacks), but HLA-B\*14:01 did not in either group. These results 533 are consistent with previous data where HLA-B\*14:02 was shown to confer protection in a 534 logistic regression model that included all HLA class I alleles with phenotypic frequency >2% 535 (33) and with our immunological findings.

536

#### 537 **DISCUSSION**

538 This study investigated HIV control mediated by HLA-B\*14. We showed that the HLA-B\*14-539 restricted Env-EL9-specific CD8+ T-cell response was more efficacious against HIV than Gag-540 DA9-specific response. In association with this, Env-specific response had significantly greater 541 function avidity, was more frequently targeted and was of higher magnitude than the Gag-542 specific response. We demonstrated that the fuctional avidity for Env-EL9 was significantly 543 higher for responses restitected by HLA-B\*14:02 than by HLA-B\*14:01. Finally, we showed a 544 significantly stronger association between HLA-B\*14:02 and protection against HIV disease 545 progression compared with the protection mediated by HLA-B\*14:01.

546

547 Higher anti-HIV efficacy of Env- compared to Gag-specific CD8+ T-cells responses is unusual 548 and, in fact, unreported until the current study. Numerous studies have suggested that Gag-549 specific CD8+ T-cell responses are associated with better disease outcome in HIV infection, are 550 more efficacious in control of HIV than other specificities and are often dominant responses in 551 elite controllers (6, 10, 18, 72-83). However, our result is consistent with studies showing that 552 non-Gag responses can also mediate viral control. In the macaque model of elite control, Env-, 553 Nef- and Vif-specific CD8+ T responses have been shown to be dominant and efficacious in viral 554 clearance (25, 84, 85). In HIV infection, a dominant HLA-B\*57-restricted Nef response was 555 present in an elite controller, although antiviral efficacy of that response has not been evaluated 556 (86). Similarly, HLA-B\*27:02, allele associated with better protection than HLA-B\*27:05 (P. 557 Goulder, unpublished data), restricts dominant CD8+ T-cell response in Nef, although as above 558 its efficacy remains to be determined. Furthermore, effective elimination of infected cells by Env-559 specific CD8+ T-cells, including HLA-B\*14-Env-EL9-restricted cells, has been reported in HIV 560 infection (87, 88). Our finding of the superior Env-specific antiviral efficacy is also consistent with 561 a recent study of HLA-B\*57/27-negative HIV elite controllers indicating that potent cytotoxic

562 capacity (measured by granzyme B expression and infected cell elimination) of HIV-specific
563 CD8+ T-cells as opposed to the identity of the targeted epitope is the determining factor in
564 mediating successful control of infection (89).

565

The data presented here are consistent with previous studies suggesting that an important factor contributing to antiviral efficacy of CD8+ T-cell responses is high functional avidity (26, 27, 90, 91). Functional avidity of the Env-EL9 response was >24-fold higher than that of the Gag-DA9specific response and correlated strongly with response magnitude; the Env-specific response was also more frequently targeted than the Gag-specific response (Fig 3). Thus, HLA-B\*14-Env-EL9 CD8+ T-cells with higher antigen sensitivity than HLA-B\*14-Gag-DA9 cells would be

572 expected to be more efficacious in controlling viral replication.

573

574 These qualitative differences between Env- and Gag-specific CD8+ T-cells were only significant 575 among HLA-B\*14:02-positive individuals (Fig 3). In the case of functional avidity, the difference 576 between the Env- and Gag-specific responses was significant even among HLA-B\*14:01-577 positive individuals, although less markedly so. However, the avidity of the Env-EL9 response 578 was still 12-fold higher in the HLA-B\*14:02-positive subjects compared to the HLA-B\*14:01-579 positive subjects. These observations suggest that despite restriction of the same epitopes by 580 these two closely-related HLA-B\*14 molecules, HIV-specific HLA-B\*14:02-restricted CD8+ T-581 cells are qualitatively different from HIV-specific HLA-B\*14:01-restricted CD8+ T-cells, and the 582 difference is primarily determined by the superior function of HLA-B\*14:02-restricted Env-EL9-583 specific CD8+ T-cells.

584

It has previously been proposed that an important mechanism by which HLA class I molecules influence rates of HIV disease progression is related to the specificity of the particular HIV epitopes that are presented (8). As described above, factors other than the specificity are

important. However, the demonstration here of the HLA-B\*14-EL9 response as both
immunodominant among HLA-B\*14-positive subjects and efficacious in suppressing HIV is
consistent with previous observations of HLA-B\*14 being associated with protection against
rapid HIV disease progression (3, 39, 41). The substantially higher functional avidity of this EnvEL9 response among HLA-B\*14:02- than HLA-B\*14:01-positive subjects is also consistent with
the findings here that HLA-B\*14:02 is significantly more protective against HIV disease
progression than HLA-B\*14:01.

595

596 These studies have focused on the two principal HLA-B\*14-restricted HIV-specific responses. 597 We have not considered other HLA-B\*14-restricted HIV-specific responses since these are the 598 only 2 that drive selection pressure on the virus (67). The labour-intensive nature of the work 599 and the consequently small number of subjects studied here limits our concluding definitively 600 that in all cases HLA-B\*14-restricted Env-EL9-specific CD8+ T-cells inhibit HIV replication more 601 effectively than HLA-B\*14-restricted Gag-DA9-specific respones. In addition, sample availability 602 precluded our comparing the capacity of HLA-B\*14:01-restricted CTL clones compared with 603 HLA-B\*14:02-restricted CTL clones to inhibit viral replication.

604

605 Structurally, HLA-B\*14:01 and HLA-B\*14:02 differ only at the position 11 (P11), with a serine 606 and an alanine, respectively (92). However, P11 is unlikely to explain the difference in HIV 607 control between the two HLA molecules, because of its 'buried' location in the α1 domain of HLA 608 near the C pocket (93, 94) where it does not contribute to interactions between HLA domains or 609 with a peptide or TCR, is not solvent-accessible and is of low variability (95, 96). The peptide-610 binding motif for HLA-B\*14:02 has previously been determined (70). Studies identifying HLA-611 B\*14-restricted epitopes reported only 2-digit HLA, thus not showing an HLA-B\*14:01 motif 612 explicitly (31, 42). However, due to lack of significant structural differences the peptide-binding 613 motif is likely to be the same for both molecules.

614

615 On the other hand, the 'buried' P11 may alter the confirmation of the nearby  $\alpha$ 1 residues or 616 affect upstream peptide processing (92). Of note, HLA-B\*14:02 and HLA-B\*14:03 differ by a 617 single amino acid in the HLA sequence at P156 but share only ~30% of their peptides (97). This 618 single difference at P156, essential in D and E peptide-binding pockets (95), may play a role in 619 the differential association of HLA-B\*14:02 and HLA-B\*14:03 with ankylosing spondylitis (97, 620 98). Previous HIV-specific studies have also shown that one amino acid difference between HLA 621 subtypes, such as HLA-B\*35:01 and HLA-B\*35:03 (99), or HLA-B\*35:01 and HLA-B\*35:08 622 (100), HLA-B\*42:01 and HLA-B\*42:02 (24), and HLA-B\*57:02 and HLA-B\*57:03 (101), is 623 sufficient to have a significant impact on disease outcome. 624 625 Another distinguishing feature between HLA-B\*14:01 and HLA-B\*14:02 alleles appears to be in 626 the selection pressure that they exert on the virus. First, the Gag-DA9 K302R mutation was 627 found exclusively in HLA-B\*14:01-positive subjects, consistent with previous large cohort studies 628 involving >3500 study subjects (67, 68). This again would point to the lack of antiviral efficacy of 629 HLA-B\*14:02-Gag-specific CD8+ T-cells. At the same time, HLA-B\*14:02 appeared to have 630 selected Env-EL9 K588Q mutation and there is a hint that this selection is associated with 631 higher viraemia and lower CD4+ T-cell counts (Figs 6C-E). Curiously, however, neither of these 632 mutations had a significant impact on viral replication, although Env-EL9-K588Q tended to have 633 a slightly lower replicative capacity than the wild type, while the opposite was true for Gag-DA9-634 K302R (Fig 6). This is particularly interesting in the case of the Gag epitope. This epitope (Gag 635 298-306) overlaps with the highly conserved major homology region (Gag 285-304) in the C-636 terminus of HIV p24 capsid, which is essential for virion assembly and stability (102, 103) and 637 previous reports showed rapid reversion of K302R in the absence of HLA-B\*14:01 (69, 104), 638 implying K302R inflicts a significant cost to viral replicative capacity. However, apparent lack of 639 impact of this mutation on viral replication was also recently reported by another group (71).

640

641 It is perhaps surprising that previous large studies investigating the relationship between HLA 642 class I type and HIV disease progression did not identify the difference between HLA-B\*14:02 643 and HLA-B\*14:01 in terms of the protective effect conferred. In some erlier studies 2-digit HLA 644 typing was employed (Hendel et al 1999) which prevented these analyses being undertaken. 645 Also, HLA-B\*14 class I subtypes are not especially prevalent, especially in African populations 646 (the phenotypic frequency of HLA-B\*14 is 6.0% versus 8.7% in the present study (Tables 1,2)) 647 and hence large study numbers are needed to achieve adequate statistical power. The current 648 analysis involved 3,259 Whites and 1,745 Blacks, and even with these numbers the protection 649 afforded by HLA-B\*14:02 in the Blacks was only evident at a p value 0.02. 650 651 In conclusion, these studies indicate that, although Gag-specific CD8+ T-cell responses may

usually have greater antiviral efficacy against HIV for the several reasons described above,
influences such as functional avidity of individual responses are also critically important factors
that may override protein-specificity in contributing to immune control of HIV infection. This
finding is relevant to the development of vaccines designed to generate effective antiviral CD8+
T-cell responses.

657

# 658 **ACKNOWLEDGEMENTS**

This work was funded by grants from the National Institutes of Health (RO1AI46995 to PJRG),

the Wellcome Trust (WT104748MA to PJRG), NIHR research capability funding (to PCM) and

the Clarendon Fund (to EML). This project has been funded in whole or in part with federal funds

662 from the Frederick National Laboratory for Cancer Research, under Contract No.

663 HHSN261200800001E (to MC). The MACS is funded primarily by the National Institute of

- Allergy and Infectious Diseases (NIAID), U01-AI35042 (Johns Hopkins University Bloomberg
- 665 School of Public Health, Joseph Margolick, PI), U01-AI35039 (Northwestern University, Steven

Wolinsky, PI), U01-AI35040 (University of California, Los Angeles, Roger Detels and Oto
Martinez MPI), U01-AI35041 (University of Pittsburgh, Charles Rinaldo, PI), and UM1-AI35043
(Johns Hopkins University Bloomberg School of Public Health, Lisa Jacobson, PI). The funders
had no role in study design, data collection and analysis, decision to publish, or preparation of
the manuscript.

671

The following reagent was obtained through the NIH AIDS Reagent Program, Division of AIDS,
NIAID, NIH: CD3.4 Bi-specific Monoclonal Antibody (Cat#12278) from Drs. Johnson Wong and
Galit Alter.

675

676 The authors have declared that no competing interests exist.

677

#### 678 **FIGURE LEGENDS**

679 Figure 1. Higher antiviral potency of B\*14:02-EL9 versus -DA9 CD8 T-cell response. (A) 680 HIV-related clinical profile of subject Subject-1; gray area shows time period during which 681 infection occurred. All viral load measurements were undetectable (<40 copies/ml) and are 682 shown below the limit of detection (LOD) of 40 copies/ml for convenience. (B) CD8+ T-cell IFN-v 683 ELISPOT responses to overlapping peptides spanning the entire HIV proteome in Subject-1. 684 Dotted line shows the cutoff magnitude (50 SFC/10<sup>6</sup> PBMC). (C) CD8+ T-cell IFN-y ELISPOT 685 responses to epitopes restricted by HLA class I alleles expressed by Subject-1. HLA-A\*36:01-686 restricted responses are not shown as these are not defined. Dotted line shows the cutoff 687 magnitude (50 SFC/10<sup>6</sup> PBMC). (D-F) Data for Subject-1; (G-J) data for Subject-2. (D,G) 688 Tetramer stainings confirming HLA-B\*14-02-Env-EL9 (top panels) and HLA-B\*14:02-Gag-DA9 689 (bottom panels) CD8+ T-cell responses in bulk (left panels) and tetramer-depleted cultures (right 690 panels). Gated on live CD3+CD4- lymphocytes around CD8+ tetramer+ cells; numbers indicate 691 % of CD8+ cells. (E,H) Viral replication (%GFP+ cells) time course in infected T1-HLA-B\*14:02positive target cells with or without effector CD8+ T-cells. Results were compared to T1-HLAB\*14:02 target cells only at the peak of viral replication using paired t-tests. (F,I) Suppressive
capacity of 'bulk' 'Env-EL9-depleted' or 'Gag-DA9-depleted' effector cells calculated as
described in the Methods. Kruskal-Wallis test with Dunn's multiple comparison test. E,F,H,I,
Error bars represent s.e.m. \*p<0.05, \*\*p<0.01, \*\*\*p<0.001. Only significant differences are</li>
shown. Legend applies to panels (E), (F), (H) and (I).

698

699 Figure 2. Suppressive capacity of epitope-specific Env and Gag CTL lines and clones. 700 Panels A-C show results for CTL lines, generated by peptide-stimulation of epitope-specific cells 701 from PBMC, sorting them and further expanding before testing in inhibition assays; panels D-F 702 show examples of clones, generated by single-cell sorting of epitope-specific cells and growing 703 them out in culture before testing their antiviral capacity. (A, D) Confirmatory tetramer stainings 704 of epitope-specific CTL lines (A) and clones (D). Gated on live CD3+CD4- cells around 705 CD8+tetramer+ cells; numbers indicate % tetramer+ cells (of CD3+CD4-). (B, E) Viral replication 706 in infected T1-HLA-B\*14:02-positive target cells with or without effector cells. Results were 707 compared to T1-HLA-B\*14:02 target cells only at the peak of viral replication using paired t-tests. 708 \*p<0.05, \*\*p<0.01, \*\*\*p<0.001, ns, not significant (p>0.05). (C, F) Suppressive capacity of 709 effector cells. Mann-Whitney U test. B,C,E,F, error bars represent s.e.m. Legend in (B) applies 710 to panels (C), (E) and (F).

711

# Figure 3. Higher functional avidity and magnitude of EL9- versus DA9-specific response.

713 (A) Functional avidity (EC50) of Env-EL9 versus Gag-DA9 CD8+ T-cell responses in all HLA-

B\*14-positive subjects (n=30, left panel) or separately in HLA-B\*14:01-expressing (n=16) or

715 HLA-B\*14:02-expressing (n=14) subjects (right panel). Lines and numbers indicate median

- values. Mann-Whitney U tests. (B) Magnitude of Env-EL9 or Gag-DA9 responses determined by
- 717 IFN-γ ELISPOT assay in all HLA-B\*14-positive subjects (n=30; left panel) or in HLA-B\*14:01-

expressing (n=16) and HLA-B\*14:02-expressing (n=14) subjects (right panel). Numbers above
the bar graphs indicate median values; error bars show interquartile ranges; Mann-Whitney U
tests. (C) Correlation between response magnitude and functional avidity in HLA-B\*14-positive
(left), HLA-B\*14:01-positive (middle) and HLA-B\*14:02-positive subjects. R and p values were
obtained by Spearman correlation. Legend for all panels is shown in panel (A).

723

# Figure 4. Differential Env-EL9 and Gag-DA9 selection pressure in B\*14:01 versus B\*14:02.

725 (A) Consensus sequences of Env-EL9 and Gag-DA9 epitopes and polymorphisms associated

with HLA-B\*14 subtypes; overlapping polymorphisms associated with non-HLA-B\*14 alleles are

also shown. Data compiled from previously published large cohort studies (67-69). (B)

728 Frequency of Env-EL9 and Gag-DA9 wild type and variant sequences in the studied HLA-B\*14-

positive subjects. Graphs at the bottom compare frequency of subjects with autologous wild type

(filled bars) or mutated (empty bars) sequence of Env-EL9 versus Gag-DA9 epitopes. Fisher's

731 Exact Tests. A,B, residues identical to the wild type are presented as '-', non-identical residues

are specified.

733

# Figure 5. K588Q and not K588R is an escape variant in HLA-B\*14-positive subjects.

(A) Representative example of responses to EL9 wildtype versus EL9 K588Q variant peptides at
different peptide concentrations by IFN-γ ELISPOT assay. Shown example is subject OX018
who has autologous EL9 K588Q variant. (B) Cross-recognition of EL9 wildtype and EL9 K588Q
(top row) versus EL9 wildtype and EL9 K588R (bottom row). Shown example is subject OX018
who has autologous EL9 K588Q variant. (C) Cross-reactivity data of wildtype EL9-specific cells
with K588Q and K588R variants for 8 H:A-B\*14-positive subjects determined by tetramer
staining.

742

743	Figure 6. Impact of Gag-DA9 and Env-EL9 escape mutants on viral fitness and HIV
744	infection outcome. (A) Replication kinetics of NL4-3 containing wild type p24 and Env
745	compared to the C-clade version of Gag-DA9 epitope and three other HLA-B*14-associated Gag
746	and Env mutants. Infectivity is expressed as %GFP-positive GXR reporter cells over 7 days after
747	infection. Error bars represent s.e.m. (B) Viral replication capacity of the viruses in A. ANOVA
748	with Dunnett's Multiple Comparison Test comparing NL4-3 versus the other viruses. Error bars
749	represent s.e.m. *p<0.05, **p<0.01, ***p<0.001, ns, not significant (p>0.05). Legend as in panel
750	(A). (C-E) Viral loads in HLA-B*14-positive (C), HLA-B*14:01-positive (D) and HLA-B*14:02-
751	positive (E) subjects with either wild type or mutated autologous sequences in Env-EL9 and
752	Gag-DA9 epitopes. X-axes indicate patients' autologous epitope sequences. Only significant p
753	values (p>0.05), obtained by Mann-Whitney U test, are shown. Horizontal bars indicate
754	medians. Wt, wild type; var, variant sequence.
755	
756	Table 1. Frequency of HLA-B*14:01 versus HLA-B*14:02 among viraemic controllers and
757	non-controllers.
758	
759	Table 2. HLA-B*14:02 is significantly enriched among viraemic contollers.

# 761 **REFERENCES**

- Migueles SA, Connors M. 2010. Long-term nonprogressive disease among untreated
   HIV-infected individuals: clinical implications of understanding immune control of HIV.
   JAMA 304:194-201.
- Kaslow RA, Carrington M, Apple R, Park L, Munoz A, Saah AJ, Goedert JJ, Winkler
   C, O'Brien SJ, Rinaldo C, Detels R, Blattner W, Phair J, Erlich H, Mann DL. 1996.
   Influence of combinations of human major histocompatibility complex genes on the
   course of HIV-1 infection. Nature Med 2:405-411.
- 769 Perevra F, Jia X, McLaren PJ, Telenti A, de Bakker PI, Walker BD, Ripke S, Brumme 3. 770 CJ, Pulit SL, Carrington M, Kadie CM, Carlson JM, Heckerman D, Graham RR, 771 Plenge RM, Deeks SG, Gianniny L, Crawford G, Sullivan J, Gonzalez E, Davies L, 772 Camargo A, Moore JM, Beattie N, Gupta S, Crenshaw A, Burtt NP, Guiducci C, 773 Gupta N, Gao X, Qi Y, Yuki Y, Piechocka-Trocha A, Cutrell E, Rosenberg R, Moss 774 KL, Lemay P, O'Leary J, Schaefer T, Verma P, Toth I, Block B, Baker B, Rothchild 775 A, Lian J, Proudfoot J, Alvino DM, Vine S, Addo MM, Allen TM, et al. 2010. The 776 major genetic determinants of HIV-1 control affect HLA class I peptide presentation. 777 Science 330:1551-1557.
- 7784.Migueles SA, Sabbaghian MS, Shupert WL, Bettinotti MP, Marincola FM, Martino L,779Hallahan CW, Selig SM, Schwartz D, Sullivan J, Connors M. 2000. HLA B\*5701 is780highly associated with restriction of virus replication in a subgroup of HIV-infected long781term nonprogressors. Proc Natl Acad Sci U S A 97:2709-2714.
- 5. Lambotte O, Boufassa F, Madec Y, Nguyen A, Goujard C, Meyer L, Rouzioux C,
   Venet A, Delfraissy JF. 2005. HIV controllers: a homogeneous group of HIV-1-infected
   patients with spontaneous control of viral replication. Clin Infect Dis 41:1053-1056.
- Kiepiela P, Ngumbela K, Thobakgale C, Ramduth D, Honeyborne I, Moodley E,
  Reddy S, de Pierres C, Mncube Z, Mkhwanazi N, Bishop K, van der Stok M, Nair K,
  Khan N, Crawford H, Payne R, Leslie A, Prado J, Prendergast A, Frater J, McCarthy
  N, Brander C, Learn GH, Nickle D, Rousseau C, Coovadia H, Mullins JI, Heckerman
  D, Walker BD, Goulder P. 2007. CD8+ T-cell responses to different HIV proteins have
  discordant associations with viral load. Nature Med 13:46-53.
- 791 7. Ngumbela KC, Day CL, Mncube Z, Nair K, Ramduth D, Thobakgale C, Moodley E, Reddy S, de Pierres C, Mkhwanazi N, Bishop K, van der Stok M, Ismail N, Honeyborne I, Crawford H, Kavanagh DG, Rousseau C, Nickle D, Mullins J, Heckerman D, Korber B, Coovadia H, Kiepiela P, Goulder PJ, Walker BD. 2008.
  795 Targeting of a CD8 T cell env epitope presented by HLA-B\*5802 is associated with markers of HIV disease progression and lack of selection pressure. AIDS Res Hum Retroviruses 24:72-82.
- 798 8. Goulder PJ, Walker BD. 2012. HIV and HLA class I: an evolving relationship. Immunity
   37:426-440.
- 8009.Matthews PC, Koyanagi M, Kloverpris HN, Harndahl M, Stryhn A, Akahoshi T,801Gatanaga H, Oka S, Juarez Molina C, Valenzuela Ponce H, Avila Rios S, Cole D,802Carlson J, Payne RP, Ogwu A, Bere A, Ndung'u T, Gounder K, Chen F, Riddell L,

- 803Luzzi G, Shapiro R, Brander C, Walker B, Sewell AK, Reyes Teran G, Heckerman D,804Hunter E, Buus S, Takiguchi M, Goulder PJ. 2012. Differential clade-specific HLA-805B\*3501 association with HIV-1 disease outcome is linked to immunogenicity of a single806Gag epitope. J Virol 86:12643-12654.
- Masemola A, Mashishi T, Khoury G, Mohube P, Mokgotho P, Vardas E, Colvin M,
  Zijenah L, Katzenstein D, Musonda R, Allen S, Kumwenda N, Taha T, Gray G,
  McIntyre J, Karim SA, Sheppard HW, Gray CM. 2004. Hierarchical targeting of subtype
  C human immunodeficiency virus type 1 proteins by CD8+ T cells: correlation with viral
  load. J Virol 78:3233-3243.
- Schneidewind A, Brockman MA, Yang R, Adam RI, Li B, Le Gall S, Rinaldo CR,
  Craggs SL, Allgaier RL, Power KA, Kuntzen T, Tung CS, LaBute MX, Mueller SM,
  Harrer T, McMichael AJ, Goulder PJ, Aiken C, Brander C, Kelleher AD, Allen TM.
  2007. Escape from the dominant HLA-B27-restricted cytotoxic T-lymphocyte response in
  Gag is associated with a dramatic reduction in human immunodeficiency virus type 1
  replication. J Virol 81:12382-12393.
- 818
  12. Crawford H, Lumm W, Leslie A, Schaefer M, Boeras D, Prado JG, Tang J, Farmer P, Ndung'u T, Lakhi S, Gilmour J, Goepfert P, Walker BD, Kaslow R, Mulenga J, Allen S, Goulder PJ, Hunter E. 2009. Evolution of HLA-B\*5703 HIV-1 escape mutations in HLA-B\*5703-positive individuals and their transmission recipients. J Exp Med 206:909-921.
- Martinez-Picado J, Prado JG, Fry EE, Pfafferott K, Leslie A, Chetty S, Thobakgale
  C, Honeyborne I, Crawford H, Matthews P, Pillay T, Rousseau C, Mullins JI,
  Brander C, Walker BD, Stuart DI, Kiepiela P, Goulder P. 2006. Fitness cost of escape
  mutations in p24 Gag in association with control of human immunodeficiency virus type
  J Virol 80:3617-3623.
- 82814.Miura T, Brockman MA, Schneidewind A, Lobritz M, Pereyra F, Rathod A, Block BL,<br/>Brumme ZL, Brumme CJ, Baker B, Rothchild AC, Li B, Trocha A, Cutrell E, Frahm<br/>N, Brander C, Toth I, Arts EJ, Allen TM, Walker BD. 2009. HLA-B57/B\*5801 human<br/>immunodeficiency virus type 1 elite controllers select for rare gag variants associated<br/>with reduced viral replication capacity and strong cytotoxic T-lymphocyte [corrected]<br/>recognition. J Virol 83:2743-2755.
- Troyer RM, McNevin J, Liu Y, Zhang SC, Krizan RW, Abraha A, Tebit DM, Zhao H,
  Avila S, Lobritz MA, McElrath MJ, Le Gall S, Mullins JI, Arts EJ. 2009. Variable
  fitness impact of HIV-1 escape mutations to cytotoxic T lymphocyte (CTL) response.
  PLoS Pathog 5:e1000365.
- 838 16. Zhu P, Chertova E, Bess J, Jr., Lifson JD, Arthur LO, Liu J, Taylor KA, Roux KH.
  839 2003. Electron tomography analysis of envelope glycoprotein trimers on HIV and simian immunodeficiency virus virions. Proc Natl Acad Sci U S A 100:15812-15817.
- Sacha JB, Chung C, Rakasz EG, Spencer SP, Jonas AK, Bean AT, Lee W, Burwitz
  BJ, Stephany JJ, Loffredo JT, Allison DB, Adnan S, Hoji A, Wilson NA, Friedrich
  TC, Lifson JD, Yang OO, Watkins DI. 2007. Gag-specific CD8+ T lymphocytes
  recognize infected cells before AIDS-virus integration and viral protein expression. J
  Immunol 178:2746-2754.

- Payne RP, Kloverpris H, Sacha JB, Brumme Z, Brumme C, Buus S, Sims S,
  Hickling S, Riddell L, Chen F, Luzzi G, Edwards A, Phillips R, Prado JG, Goulder
  PJ. 2010. Efficacious early antiviral activity of HIV Gag- and Pol-specific HLA-B 2705restricted CD8+ T cells. J Virol 84:10543-10557.
- Kloverpris HN, Payne RP, Sacha JB, Rasaiyaah JT, Chen F, Takiguchi M, Yang OO,
  Towers GJ, Goulder P, Prado JG. 2013. Early antigen presentation of protective HIV-1
  KF11Gag and KK10Gag epitopes from incoming viral particles facilitates rapid
  recognition of infected cells by specific CD8+ T cells. J Virol 87:2628-2638.
- Sacha JB, Chung C, Reed J, Jonas AK, Bean AT, Spencer SP, Lee W, Vojnov L,
   Rudersdorf R, Friedrich TC, Wilson NA, Lifson JD, Watkins DI. 2007. Pol-specific
   CD8+ T cells recognize simian immunodeficiency virus-infected cells prior to Nef mediated major histocompatibility complex class I downregulation. J Virol 81:11703 11712.
- 859 21. Collins KL, Chen BK, Kalams SA, Walker BD, Baltimore D. 1998. HIV-1 Nef protein
   860 protects infected primary cells against killing by cytotoxic T lymphocytes. Nature
   391:397-401.
- Yang OO, Nguyen PT, Kalams SA, Dorfman T, Gottlinger HG, Stewart S, Chen IS,
   Threlkeld S, Walker BD. 2002. Nef-mediated resistance of human immunodeficiency
   virus type 1 to antiviral cytotoxic T lymphocytes. J Virol 76:1626-1631.
- Honeyborne I, Prendergast A, Pereyra F, Leslie A, Crawford H, Payne R, Reddy S,
  Bishop K, Moodley E, Nair K, van der Stok M, McCarthy N, Rousseau CM, Addo M,
  Mullins JI, Brander C, Kiepiela P, Walker BD, Goulder PJ. 2007. Control of human
  immunodeficiency virus type 1 is associated with HLA-B\*13 and targeting of multiple gagspecific CD8+ T-cell epitopes. J Virol 81:3667-3672.
- Kloverpris HN, Harndahl M, Leslie AJ, Carlson JM, Ismail N, van der Stok M, Huang
  KH, Chen F, Riddell L, Steyn D, Goedhals D, van Vuuren C, Frater J, Walker BD,
  Carrington M, Ndung'u T, Buus S, Goulder P. 2012. HIV control through a single
  nucleotide on the HLA-B locus. J Virol 86:11493-11500.
- 874 25. Mudd PA, Martins MA, Ericsen AJ, Tully DC, Power KA, Bean AT, Piaskowski SM,
  875 Duan L, Seese A, Gladden AD, Weisgrau KL, Furlott JR, Kim YI, Veloso de Santana
  876 MG, Rakasz E, Capuano S, 3rd, Wilson NA, Bonaldo MC, Galler R, Allison DB,
  877 Piatak M, Jr., Haase AT, Lifson JD, Allen TM, Watkins DI. 2012. Vaccine-induced
  878 CD8+ T cells control AIDS virus replication. Nature 491:129-133.
- Almeida JR, Price DA, Papagno L, Arkoub ZA, Sauce D, Bornstein E, Asher TE,
  Samri A, Schnuriger A, Theodorou I, Costagliola D, Rouzioux C, Agut H, Marcelin
  AG, Douek D, Autran B, Appay V. 2007. Superior control of HIV-1 replication by CD8+
  T cells is reflected by their avidity, polyfunctionality, and clonal turnover. J Exp Med
  204:2473-2485.
- Almeida JR, Sauce D, Price DA, Papagno L, Shin SY, Moris A, Larsen M, Pancino
   G, Douek DC, Autran B, Saez-Cirion A, Appay V. 2009. Antigen sensitivity is a major
   determinant of CD8+ T-cell polyfunctionality and HIV-suppressive activity. Blood
   113:6351-6360.

- Betts MR, Nason MC, West SM, De Rosa SC, Migueles SA, Abraham J, Lederman
   MM, Benito JM, Goepfert PA, Connors M, Roederer M, Koup RA. 2006. HIV
   nonprogressors preferentially maintain highly functional HIV-specific CD8+ T cells. Blood
   107:4781-4789.
- Migueles SA, Osborne CM, Royce C, Compton AA, Joshi RP, Weeks KA, Rood JE, Berkley AM, Sacha JB, Cogliano-Shutta NA, Lloyd M, Roby G, Kwan R, McLaughlin M, Stallings S, Rehm C, O'Shea MA, Mican J, Packard BZ, Komoriya A, Palmer S, Wiegand AP, Maldarelli F, Coffin JM, Mellors JW, Hallahan CW, Follman DA, Connors M. 2008. Lytic granule loading of CD8+ T cells is required for HIV-infected cell elimination associated with immune control. Immunity 29:1009-1021.
- Migueles SA, Laborico AC, Shupert WL, Sabbaghian MS, Rabin R, Hallahan CW,
   Van Baarle D, Kostense S, Miedema F, McLaughlin M, Ehler L, Metcalf J, Liu S,
   Connors M. 2002. HIV-specific CD8+ T cell proliferation is coupled to perforin
   expression and is maintained in nonprogressors. Nat Immunol 3:1061-1068.
- 31. Johnson RP, Trocha A, Buchanan TM, Walker BD. 1992. Identification of overlapping
   HLA class I-restricted cytotoxic T cell epitopes in a conserved region of the human
   immunodeficiency virus type 1 envelope glycoprotein: definition of minimum epitopes and
   analysis of the effects of sequence variation. J Exp Med 175:961-971.
- 82. Kalams SA, Johnson RP, Trocha AK, Dynan MJ, Ngo HS, D'Aquila RT, Kurnick JT,
  Walker BD. 1994. Longitudinal analysis of T cell receptor (TCR) gene usage by human
  immunodeficiency virus 1 envelope-specific cytotoxic T lymphocyte clones reveals a
  limited TCR repertoire. J Exp Med 179:1261-1271.
- 33. Bashirova AA, Martin-Gayo E, Jones DC, Qi Y, Apps R, Gao X, Burke PS, Taylor
  911 CJ, Rogich J, Wolinsky S, Bream JH, Duggal P, Hussain S, Martinson J, Weintrob
  912 A, Kirk GD, Fellay J, Buchbinder SP, Goedert JJ, Deeks SG, Pereyra F, Trowsdale
  913 J, Lichterfeld M, Telenti A, Walker BD, Allen RL, Carrington M, Yu XG. 2014. LILRB2
  914 interaction with HLA class I correlates with control of HIV-1 infection. PLoS Genet
  915 10:e1004196.
- 91634.Migueles SA, Laborico AC, Imamichi H, Shupert WL, Royce C, McLaughlin M, Ehler917L, Metcalf J, Liu S, Hallahan CW, Connors M. 2003. The differential ability of HLA918B\*5701+ long-term nonprogressors and progressors to restrict human immunodeficiency919virus replication is not caused by loss of recognition of autologous viral gag sequences. J920Virol 77:6889-6898.
- Migueles SA, Weeks KA, Nou E, Berkley AM, Rood JE, Osborne CM, Hallahan CW,
   Cogliano-Shutta NA, Metcalf JA, McLaughlin M, Kwan R, Mican JM, Davey RT, Jr.,
   Connors M. 2009. Defective human immunodeficiency virus-specific CD8+ T-cell
   polyfunctionality, proliferation, and cytotoxicity are not restored by antiretroviral therapy. J
   Virol 83:11876-11889.
- 92636.Horton H, Frank I, Baydo R, Jalbert E, Penn J, Wilson S, McNevin JP, McSweyn927MD, Lee D, Huang Y, De Rosa SC, McElrath MJ. 2006. Preservation of T cell928proliferation restricted by protective HLA alleles is critical for immune control of HIV-1929infection. J Immunol 177:7406-7415.

- 930 37. Saez-Cirion A, Lacabaratz C, Lambotte O, Versmisse P, Urrutia A, Boufassa F,
  931 Barre-Sinoussi F, Delfraissy JF, Sinet M, Pancino G, Venet A. 2007. HIV controllers
  932 exhibit potent CD8 T cell capacity to suppress HIV infection ex vivo and peculiar
  933 cytotoxic T lymphocyte activation phenotype. Proc Natl Acad Sci U S A 104:6776-6781.
- 38. Chen H, Ndhlovu ZM, Liu D, Porter LC, Fang JW, Darko S, Brockman MA, Miura T,
  Brumme ZL, Schneidewind A, Piechocka-Trocha A, Cesa KT, Sela J, Cung TD, Toth
  I, Pereyra F, Yu XG, Douek DC, Kaufmann DE, Allen TM, Walker BD. 2012. TCR
  clonotypes modulate the protective effect of HLA class I molecules in HIV-1 infection. Nat
  Immunol 13:691-700.
- 839. Kiepiela P, Leslie AJ, Honeyborne I, Ramduth D, Thobakgale C, Chetty S,
  840 Rathnavalu P, Moore C, Pfafferott KJ, Hilton L, Zimbwa P, Moore S, Allen T,
  841 Brander C, Addo MM, Altfeld M, James I, Mallal S, Bunce M, Barber LD, Szinger J,
  942 Day C, Klenerman P, Mullins J, Korber B, Coovadia HM, Walker BD, Goulder PJ.
  943 2004. Dominant influence of HLA-B in mediating the potential co-evolution of HIV and
  944 HLA. Nature 432:769-775.
- 40. Leslie A, Matthews PC, Listgarten J, Carlson JM, Kadie C, Ndung'u T, Brander C,
  646
  647
  648
  749
  749
  749
  749
  740
  740
  740
  740
  740
  740
  740
  740
  740
  740
  740
  740
  740
  740
  740
  740
  740
  740
  740
  740
  740
  740
  740
  740
  740
  740
  740
  740
  740
  740
  740
  740
  740
  740
  740
  740
  740
  740
  740
  740
  740
  740
  740
  740
  740
  740
  740
  740
  740
  740
  740
  740
  740
  740
  740
  740
  740
  740
  740
  740
  740
  740
  740
  740
  740
  740
  740
  740
  740
  740
  740
  740
  740
  740
  740
  740
  740
  740
  740
  740
  740
  740
  740
  740
  740
  740
  740
  740
  740
  740
  740
  740
  740
  740
  740
  740
  740
  740
  740
  740
  740
  740
  740
  740
  740
  740
  740
  740
  740
  740
  740
  740
  740
  740
  740
  740
  740
  740
  740
  740
  740
  740
  740
  740
  740
  740
  740
  740
  740
  740
  740
  740
  740
  740
  740
  740
  740
  740
  740
  740
  740
  740
  740</li
- 94841.Hendel H, Caillat-Zucman S, Lebuanec H, Carrington M, O'Brien S, Andrieu JM,949Schachter F, Zagury D, Rappaport J, Winkler C, Nelson GW, Zagury JF. 1999. New950class I and II HLA alleles strongly associated with opposite patterns of progression to951AIDS. J Immunol 162:6942-6946.
- 42. Harrer T, Harrer E, Kalams SA, Barbosa P, Trocha A, Johnson RP, Elbeik T,
  Feinberg MB, Buchbinder SP, Walker BD. 1996. Cytotoxic T lymphocytes in asymptomatic long-term nonprogressing HIV-1 infection. Breadth and specificity of the response and relation to in vivo viral quasispecies in a person with prolonged infection and low viral load. J Immunol 156:2616-2623.
- Payne R, Muenchhoff M, Mann J, Roberts HE, Matthews P, Adland E, Hempenstall
  A, Huang KH, Brockman M, Brumme Z, Sinclair M, Miura T, Frater J, Essex M,
  Shapiro R, Walker BD, Ndung'u T, McLean AR, Carlson JM, Goulder PJ. 2014.
  Impact of HLA-driven HIV adaptation on virulence in populations of high HIV
  seroprevalence. Proc Natl Acad Sci U S A 111:E5393-5400.
- 44. Hunt PW, Landay AL, Sinclair E, Martinson JA, Hatano H, Emu B, Norris PJ, Busch
  MP, Martin JN, Brooks C, McCune JM, Deeks SG. 2011. A low T regulatory cell
  response may contribute to both viral control and generalized immune activation in HIV
  controllers. PLoS One 6:e15924.
- 966 45. Phair J, Jacobson L, Detels R, Rinaldo C, Saah A, Schrager L, Munoz A. 1992.
  967 Acquired immune deficiency syndrome occurring within 5 years of infection with human 968 immunodeficiency virus type-1: the Multicenter AIDS Cohort Study. J Acquir Immune 969 Defic Syndr 5:490-496.
- 97046.Goedert JJ, Kessler CM, Aledort LM, Biggar RJ, Andes WA, White GC, 2nd,971Drummond JE, Vaidya K, Mann DL, Eyster ME, Ragni MV, Lederman MM, Cohen

- AR, Bray GL, Rosenberg PS, Friedman RM, Hilgartner MW, Blattner WA, Kroner B,
  Gail MH. 1989. A prospective study of human immunodeficiency virus type 1 infection
  and the development of AIDS in subjects with hemophilia. N Engl J Med 321:1141-1148.
- 47. Hunt PW, Martin JN, Sinclair E, Bredt B, Hagos E, Lampiris H, Deeks SG. 2003. T
  976 cell activation is associated with lower CD4+ T cell gains in human immunodeficiency
  977 virus-infected patients with sustained viral suppression during antiretroviral therapy. J
  978 Infect Dis 187:1534-1543.
- 979 48. Schoeni-Affolter F, Ledergerber B, Rickenbach M, Rudin C, Gunthard HF, Telenti A,
   980 Furrer H, Yerly S, Francioli P. 2010. Cohort profile: the Swiss HIV Cohort study. Int J
   981 Epidemiol 39:1179-1189.
- 49. Leisner C, Loeth N, Lamberth K, Justesen S, Sylvester-Hvid C, Schmidt EG,
  983 Claesson M, Buus S, Stryhn A. 2008. One-pot, mix-and-read peptide-MHC tetramers.
  984 PLoS One 3:e1678.
- 985 50. Hess PR, Barnes C, Woolard MD, Johnson MD, Cullen JM, Collins EJ, Frelinger JA.
  986 2007. Selective deletion of antigen-specific CD8+ T cells by MHC class I tetramers
  987 coupled to the type I ribosome-inactivating protein saporin. Blood 109:3300-3307.
- Hess SM, Young EF, Miller KR, Vincent BG, Buntzman AS, Collins EJ, Frelinger JA,
   Hess PR. 2013. Deletion of naive T cells recognizing the minor histocompatibility antigen
   HY with toxin-coupled peptide-MHC class I tetramers inhibits cognate CTL responses
   and alters immunodominance. Transpl Immunol 29:138-145.
- 99252.Penaloza-MacMaster P, Masopust D, Ahmed R. 2009. T-cell reconstitution without T-<br/>cell immunopathology in two models of T-cell-mediated tissue destruction. Immunology<br/>128:164-171.
- 53. Sims S, Bolinger B, Klenerman P. 2015. Increasing inflationary T-cell responses
   following transient depletion of MCMV-specific memory T cells. Eur J Immunol 45:113 118.
- 99854.Vincent BG, Young EF, Buntzman AS, Stevens R, Kepler TB, Tisch RM, Frelinger999JA, Hess PR. 2010. Toxin-coupled MHC class I tetramers can specifically ablate1000autoreactive CD8+ T cells and delay diabetes in nonobese diabetic mice. J Immunol1001184:4196-4204.
- 100255.Wong JT, Colvin RB. 1987. Bi-specific monoclonal antibodies: selective binding and<br/>complement fixation to cells that express two different surface antigens. J Immunol<br/>139:1369-1374.
- 100556.Jones N, Agrawal D, Elrefaei M, Hanson A, Novitsky V, Wong JT, Cao H. 2003.1006Evaluation of antigen-specific responses using in vitro enriched T cells. J Immunol1007Methods 274:139-147.
- 100857.Chen H, Piechocka-Trocha A, Miura T, Brockman MA, Julg BD, Baker BM,1009Rothchild AC, Block BL, Schneidewind A, Koibuchi T, Pereyra F, Allen TM, Walker1010BD. 2009. Differential neutralization of human immunodeficiency virus (HIV) replication in1011autologous CD4 T cells by HIV-specific cytotoxic T lymphocytes. J Virol 83:3138-3149.


- 101258.Saez-Cirion A, Shin SY, Versmisse P, Barre-Sinoussi F, Pancino G. 2010. Ex vivo T1013cell-based HIV suppression assay to evaluate HIV-specific CD8+ T-cell responses. Nat1014Protoc 5:1033-1041.
- 101559.Salter RD, Howell DN, Cresswell P. 1985. Genes regulating HLA class I antigen1016expression in T-B lymphoblast hybrids. Immunogenetics 21:235-246.
- 1017 60. LLano A FN, Brander C. 2009. How to Optimally Define Optimal Cytotoxic T
   1018 Lymphocyte Epitopes in HIV Infection?, p 1-3-5. Theoretical Biology and Biophysics
   1019 Group, Los Alamos National Laboratory, Los Alamos, NM.
- Altfeld MA, Trocha A, Eldridge RL, Rosenberg ES, Phillips MN, Addo MM, Sekaly
   RP, Kalams SA, Burchett SA, McIntosh K, Walker BD, Goulder PJ. 2000.
   Identification of dominant optimal HLA-B60- and HLA-B61-restricted cytotoxic T Imphocyte (CTL) epitopes: rapid characterization of CTL responses by enzyme-linked
   immunospot assay. J Virol 74:8541-8549.
- 102562.Addo MM, Yu XG, Rathod A, Cohen D, Eldridge RL, Strick D, Johnston MN,1026Corcoran C, Wurcel AG, Fitzpatrick CA, Feeney ME, Rodriguez WR, Basgoz N,1027Draenert R, Stone DR, Brander C, Goulder PJ, Rosenberg ES, Altfeld M, Walker BD.10282003. Comprehensive epitope analysis of human immunodeficiency virus type 1 (HIV-1)-1029specific T-cell responses directed against the entire expressed HIV-1 genome1030demonstrate broadly directed responses, but no correlation to viral load. J Virol 77:2081-10312092.
- 103263.Brockman MA, Schneidewind A, Lahaie M, Schmidt A, Miura T, Desouza I, Ryvkin1033F, Derdeyn CA, Allen S, Hunter E, Mulenga J, Goepfert PA, Walker BD, Allen TM.10342007. Escape and compensation from early HLA-B57-mediated cytotoxic T-lymphocyte1035pressure on human immunodeficiency virus type 1 Gag alter capsid interactions with1036cyclophilin A. J Virol 81:12608-12618.
- 103764.Leslie AJ, Pfafferott KJ, Chetty P, Draenert R, Addo MM, Feeney M, Tang Y, Holmes1038EC, Allen T, Prado JG, Altfeld M, Brander C, Dixon C, Ramduth D, Jeena P, Thomas1039SA, St John A, Roach TA, Kupfer B, Luzzi G, Edwards A, Taylor G, Lyall H, Tudor-1040Williams G, Novelli V, Martinez-Picado J, Kiepiela P, Walker BD, Goulder PJ. 2004.1041HIV evolution: CTL escape mutation and reversion after transmission. Nat Med 10:282-1042289.
- 104365.Matthews PC, Adland E, Listgarten J, Leslie A, Mkhwanazi N, Carlson JM, Harndahl1044M, Stryhn A, Payne RP, Ogwu A, Huang KH, Frater J, Paioni P, Kloverpris H, Jooste1045P, Goedhals D, van Vuuren C, Steyn D, Riddell L, Chen F, Luzzi G, Balachandran T,1046Ndung'u T, Buus S, Carrington M, Shapiro R, Heckerman D, Goulder PJ. 2011. HLA-1047A\*7401-mediated control of HIV viremia is independent of its linkage disequilibrium with1048HLA-B\*5703. J Immunol 186:5675-5686.
- 1049
   1050
   1050
   1051
   1052
   Llano A, Carrillo J, Mothe B, Ruiz L, Marfil S, Garcia E, Yuste E, Sanchez V, Clotet
   B, Blanco J, Brander C. 2013. Expansion of antibody secreting cells and modulation of neutralizing antibody activity in HIV infected individuals undergoing structured treatment interruptions. J Transl Med 11:48.


- 1053
  1054
  1054
  1055
  1056
  1056
  1057
  Carlson JM, Brumme CJ, Martin E, Listgarten J, Brockman MA, Le AQ, Chui CK, Cotton LA, Knapp DJ, Riddler SA, Haubrich R, Nelson G, Pfeifer N, Deziel CE, Heckerman D, Apps R, Carrington M, Mallal S, Harrigan PR, John M, Brumme ZL.
  2012. Correlates of protective cellular immunity revealed by analysis of population-level immune escape pathways in HIV-1. J Virol 86:13202-13216.
- 1058
  68. Carlson JM, Schaefer M, Monaco DC, Batorsky R, Claiborne DT, Prince J, Deymier
  1059
  MJ, Ende ZS, Klatt NR, DeZiel CE, Lin TH, Peng J, Seese AM, Shapiro R, Frater J,
  1060
  Ndung'u T, Tang J, Goepfert P, Gilmour J, Price MA, Kilembe W, Heckerman D,
  1061
  Goulder PJ, Allen TM, Allen S, Hunter E. 2014. HIV transmission. Selection bias at the
  heterosexual HIV-1 transmission bottleneck. Science 345:1254031.
- 106369.Matthews PC, Prendergast A, Leslie A, Crawford H, Payne R, Rousseau C, Rolland1064M, Honeyborne I, Carlson J, Kadie C, Brander C, Bishop K, Mlotshwa N, Mullins JI,1065Coovadia H, Ndung'u T, Walker BD, Heckerman D, Goulder PJ. 2008. Central role of1066reverting mutations in HLA associations with human immunodeficiency virus set point. J1067Virol 82:8548-8559.
- 106870.DiBrino M, Parker KC, Margulies DH, Shiloach J, Turner RV, Biddison WE, Coligan1069JE. 1994. The HLA-B14 peptide binding site can accommodate peptides with different1070combinations of anchor residues. J Biol Chem 269:32426-32434.
- 107171.Boutwell CL, Carlson JM, Lin TH, Seese A, Power KA, Peng J, Tang Y, Brumme ZL,1072Heckerman D, Schneidewind A, Allen TM. 2013. Frequent and variable cytotoxic-T-1073lymphocyte escape-associated fitness costs in the human immunodeficiency virus type 11074subtype B Gag proteins. J Virol 87:3952-3965.
- 1075 72. Saez-Cirion A, Sinet M, Shin SY, Urrutia A, Versmisse P, Lacabaratz C, Boufassa F, 1076 Avettand-Fenoel V, Rouzioux C, Delfraissy JF, Barre-Sinoussi F, Lambotte O, 1077 Venet A, Pancino G. 2009. Heterogeneity in HIV suppression by CD8 T cells from HIV 1078 controllers: association with Gag-specific CD8 T cell responses. J Immunol 182:7828-1079 7837.
- 108073.Riviere Y, McChesney MB, Porrot F, Tanneau-Salvadori F, Sansonetti P, Lopez O,1081Pialoux G, Feuillie V, Mollereau M, Chamaret S, Tekaja F, Montagnier L. 1995. Gag-1082specific cytotoxic responses to HIV type 1 are associated with a decreased risk of1083progression to AIDS-related complex or AIDS. AIDS Res Hum Retroviruses 11:903-907.
- 1084 74. Klein MR, van Baalen CA, Holwerda AM, Kerkhof Garde SR, Bende RJ, Keet IP,
   1085 Eeftinck-Schattenkerk JK, Osterhaus AD, Schuitemaker H, Miedema F. 1995.
   1086 Kinetics of Gag-specific cytotoxic T lymphocyte responses during the clinical course of
   1087 HIV-1 infection: a longitudinal analysis of rapid progressors and long-term
   1088 asymptomatics. J Exp Med 181:1365-1372.
- 1089 75. Ogg GS, Jin X, Bonhoeffer S, Dunbar PR, Nowak MA, Monard S, Segal JP, Cao Y,
   1090 Rowland-Jones SL, Cerundolo V, Hurley A, Markowitz M, Ho DD, Nixon DF,
   1091 McMichael AJ. 1998. Quantitation of HIV-1-specific cytotoxic T lymphocytes and plasma
   1092 load of viral RNA. Science 279:2103-2106.
- 109376.Barouch DH, Kunstman J, Kuroda MJ, Schmitz JE, Santra S, Peyerl FW, Krivulka1094GR, Beaudry K, Lifton MA, Gorgone DA, Montefiori DC, Lewis MG, Wolinsky SM,

- 1095Letvin NL. 2002. Eventual AIDS vaccine failure in a rhesus monkey by viral escape from1096cytotoxic T lymphocytes. Nature 415:335-339.
- 1097 77. Barouch DH, Kunstman J, Glowczwskie J, Kunstman KJ, Egan MA, Peyerl FW,
   1098 Santra S, Kuroda MJ, Schmitz JE, Beaudry K, Krivulka GR, Lifton MA, Gorgone DA,
   1099 Wolinsky SM, Letvin NL. 2003. Viral escape from dominant simian immunodeficiency
   1100 virus epitope-specific cytotoxic T lymphocytes in DNA-vaccinated rhesus monkeys. J
   1101 Virol 77:7367-7375.
- 110278.Janes H, Friedrich DP, Krambrink A, Smith RJ, Kallas EG, Horton H, Casimiro DR,1103Carrington M, Geraghty DE, Gilbert PB, McElrath MJ, Frahm N. 2013. Vaccine-1104induced gag-specific T cells are associated with reduced viremia after HIV-1 infection. J1105Infect Dis 208:1231-1239.
- 110679.Edwards BH, Bansal A, Sabbaj S, Bakari J, Mulligan MJ, Goepfert PA. 2002.1107Magnitude of functional CD8+ T-cell responses to the gag protein of human1108immunodeficiency virus type 1 correlates inversely with viral load in plasma. J Virol110976:2298-2305.
- Novitsky V, Gilbert P, Peter T, McLane MF, Gaolekwe S, Rybak N, Thior I, Ndung'u
  T, Marlink R, Lee TH, Essex M. 2003. Association between virus-specific T-cell
  responses and plasma viral load in human immunodeficiency virus type 1 subtype C
  infection. J Virol 77:882-890.
- 81. Zuniga R, Lucchetti A, Galvan P, Sanchez S, Sanchez C, Hernandez A, Sanchez H,
  Frahm N, Linde CH, Hewitt HS, Hildebrand W, Altfeld M, Allen TM, Walker BD,
  Korber BT, Leitner T, Sanchez J, Brander C. 2006. Relative dominance of Gag p24specific cytotoxic T lymphocytes is associated with human immunodeficiency virus
  control. J Virol 80:3122-3125.
- Beldmacher C, Currier JR, Herrmann E, Haule A, Kuta E, McCutchan F, Njovu L,
  Geis S, Hoffmann O, Maboko L, Williamson C, Birx D, Meyerhans A, Cox J,
  Hoelscher M. 2007. CD8 T-cell recognition of multiple epitopes within specific Gag
  regions is associated with maintenance of a low steady-state viremia in human
  immunodeficiency virus type 1-seropositive patients. J Virol 81:2440-2448.
- 83. Streeck H, Lichterfeld M, Alter G, Meier A, Teigen N, Yassine-Diab B, Sidhu HK,
  Little S, Kelleher A, Routy JP, Rosenberg ES, Sekaly RP, Walker BD, Altfeld M.
  2007. Recognition of a defined region within p24 gag by CD8+ T cells during primary
  human immunodeficiency virus type 1 infection in individuals expressing protective HLA
  class I alleles. J Virol 81:7725-7731.
- Maness NJ, Yant LJ, Chung C, Loffredo JT, Friedrich TC, Piaskowski SM, Furlott J, May GE, Soma T, Leon EJ, Wilson NA, Piontkivska H, Hughes AL, Sidney J, Sette A, Watkins DI. 2008. Comprehensive immunological evaluation reveals surprisingly few differences between elite controller and progressor Mamu-B\*17-positive simian immunodeficiency virus-infected rhesus macaques. J Virol 82:5245-5254.
- 113485.Valentine LE, Loffredo JT, Bean AT, Leon EJ, MacNair CE, Beal DR, Piaskowski1135SM, Klimentidis YC, Lank SM, Wiseman RW, Weinfurter JT, May GE, Rakasz EG,1136Wilson NA, Friedrich TC, O'Connor DH, Allison DB, Watkins DI. 2009. Infection with

- 1137 "escaped" virus variants impairs control of simian immunodeficiency virus SIVmac239
   1138 replication in Mamu-B\*08-positive macaques. J Virol 83:11514-11527.
- 113986.Jessen H, Allen TM, Streeck H. 2014. How a single patient influenced HIV research--114015-year follow-up. N Engl J Med 370:682-683.
- 1141 87. Yang OO, Kalams SA, Trocha A, Cao H, Luster A, Johnson RP, Walker BD. 1997.
  1142 Suppression of human immunodeficiency virus type 1 replication by CD8+ cells:
  1143 evidence for HLA class I-restricted triggering of cytolytic and noncytolytic mechanisms. J
  1144 Virol 71:3120-3128.
- 114588.Chen DY, Balamurugan A, Ng HL, Yang OO. 2011. Antiviral activity of human1146immunodeficiency virus type 1 Gag-specific cytotoxic T lymphocyte targeting is not1147necessarily intrinsically superior to envelope targeting. J Virol 85:2474-2478.
- 114889.Migueles SA, Mendoza D, Zimmerman MG, Martins KM, Toulmin SA, Kelly EP,1149Peterson BA, Johnson SA, Galson E, Poropatich KO, Patamawenu A, Imamichi H,1150Ober A, Rehm CA, Jones S, Hallahan CW, Follmann DA, Connors M. 2015. CD8(+)1151T-cell Cytotoxic Capacity Associated with Human Immunodeficiency Virus-1 Control Can1152Be Mediated through Various Epitopes and Human Leukocyte Antigen Types.1153EBioMedicine 2:46-58.
- 115490.Lecuroux C, Saez-Cirion A, Girault I, Versmisse P, Boufassa F, Avettand-Fenoel V,1155Rouzioux C, Meyer L, Pancino G, Lambotte O, Sinet M, Venet A. 2014. Both HLA-1156B\*57 and plasma HIV RNA levels contribute to the HIV-specific CD8+ T cell response in1157HIV controllers. J Virol 88:176-187.
- Mothe B, Llano A, Ibarrondo J, Zamarreno J, Schiaulini M, Miranda C, Ruiz-Riol M,
  Berger CT, Herrero MJ, Palou E, Plana M, Rolland M, Khatri A, Heckerman D,
  Pereyra F, Walker BD, Weiner D, Paredes R, Clotet B, Felber BK, Pavlakis GN,
  Mullins JI, Brander C. 2012. CTL responses of high functional avidity and broad variant
  cross-reactivity are associated with HIV control. PLoS One 7:e29717.
- 116392.Domena JD, Azumi K, Bias WB, Parham P. 1993. B\*1401 encodes the B64 antigen:1164the B64 and B65 splits of B14 differ only at residue 11, a buried amino acid. Tissue1165Antigens 41:110-111.
- 116693.Bjorkman PJ, Saper MA, Samraoui B, Bennett WS, Strominger JL, Wiley DC. 1987.1167Structure of the human class I histocompatibility antigen, HLA-A2. Nature 329:506-512.
- 116894.Garrett TP, Saper MA, Bjorkman PJ, Strominger JL, Wiley DC. 1989. Specificity1169pockets for the side chains of peptide antigens in HLA-Aw68. Nature 342:692-696.
- 1170 95. Saper MA, Bjorkman PJ, Wiley DC. 1991. Refined structure of the human
  1171 histocompatibility antigen HLA-A2 at 2.6 A resolution. J Mol Biol 219:277-319.
- 117296.Parham P, Lomen CE, Lawlor DA, Ways JP, Holmes N, Coppin HL, Salter RD, Wan1173AM, Ennis PD. 1988. Nature of polymorphism in HLA-A, -B, and -C molecules. Proc Natl1174Acad Sci U S A 85:4005-4009.

- 117597.Merino E, Montserrat V, Paradela A, Lopez de Castro JA. 2005. Two HLA-B141176subtypes (B\*1402 and B\*1403) differentially associated with ankylosing spondylitis differ1177substantially in peptide specificity but have limited peptide and T-cell epitope sharing with1178HLA-B27. J Biol Chem 280:35868-35880.
- 1179 98. Lopez-Larrea C, Mijiyawa M, Gonzalez S, Fernandez-Morera JL, Blanco-Gelaz MA,
   1180 Martinez-Borra J, Lopez-Vazquez A. 2002. Association of ankylosing spondylitis with
   1181 HLA-B\*1403 in a West African population. Arthritis Rheum 46:2968-2971.
- 1182 99. Gao X, Nelson GW, Karacki P, Martin MP, Phair J, Kaslow R, Goedert JJ,
  1183 Buchbinder S, Hoots K, Vlahov D, O'Brien SJ, Carrington M. 2001. Effect of a single
  1184 amino acid change in MHC class I molecules on the rate of progression to AIDS. N Engl
  1185 J Med 344:1668-1675.
- 100. Juarez-Molina CI, Valenzuela-Ponce H, Avila-Rios S, Garrido-Rodriguez D, Garcia Tellez T, Soto-Nava M, Garcia-Morales C, Goulder P, Reyes-Teran G. 2014. Impact of
   HLA-B\*35 subtype differences on HIV disease outcome in Mexico. AIDS 28:1687-1690.
- 1189
   101. Kloverpris HN, Stryhn A, Harndahl M, van der Stok M, Payne RP, Matthews PC,
   Chen F, Riddell L, Walker BD, Ndung'u T, Buus S, Goulder P. 2012. HLA-B\*57
   Micropolymorphism shapes HLA allele-specific epitope immunogenicity, selection
   pressure, and HIV immune control. J Virol 86:919-929.
- 102. Wagner R, Leschonsky B, Harrer E, Paulus C, Weber C, Walker BD, Buchbinder S,
  Wolf H, Kalden JR, Harrer T. 1999. Molecular and functional analysis of a conserved
  CTL epitope in HIV-1 p24 recognized from a long-term nonprogressor: constraints on
  immune escape associated with targeting a sequence essential for viral replication. J
  Immunol 162:3727-3734.
- 1198
   103. Zhao G, Perilla JR, Yufenyuy EL, Meng X, Chen B, Ning J, Ahn J, Gronenborn AM,
   Schulten K, Aiken C, Zhang P. 2013. Mature HIV-1 capsid structure by cryo-electron
   microscopy and all-atom molecular dynamics. Nature 497:643-646.
- 1201
   104. Koibuchi T, Allen TM, Lichterfeld M, Mui SK, O'Sullivan KM, Trocha A, Kalams SA, Johnson RP, Walker BD. 2005. Limited sequence evolution within persistently targeted CD8 epitopes in chronic human immunodeficiency virus type 1 infection. J Virol **79:**8171-8181.








Fig 3






Fig 4





C										
	OX018 K588Q	N079 K588Q	H016 K588Q	R117 K588Q	R055	0026 K588Q	0145 wt	H006	median	
Env EL9 wt-specific	4.4%	6.9%	0.3%	0.6%	0.1%	1.4%	0.5%	2.8%	1.0%	
Env EL9 wt total	4.6%	6.9%	0.3%	0.6%	0.1%	2.0%	0.5%	4.5%	1.3%	
K588Q-specific	1.2%	0.3%	1.1%	1.7%	0.5%	0.9%	0.3%	1.7%	1.1%	
K588Q total	1.2%	0.4%	1.1%	1.7%	0.5%	1.5%	0.3%	3.3%	1.2%	
Cross-reactive wt/K588Q	0.2%	0.1%	0.0%	0.0%	0.0%	0.6%	0.0%	1.7%	0.1%	
Env EL9 wt-specific	0.6%	0.5%	0.2%	0.1%	0.1%	0.6%	0.3%	0.2%	0.3%	
Env EL9 wt total	3.9%	5.8%	0.2%	0.6%	0.2%	1.9%	0.6%	3.7%	1.3%	
K588R-specific	1.5%	1.6%	0.1%	0.3%	1.6%	0.1%	0.2%	2.3%	0.9%	
K588R total	4.8%	6.8%	0.1%	0.9%	1.7%	1.3%	0.5%	5.8%	1.5%	
Cross-reactive wt/K588R	3.3%	5.2%	0.0%	0.5%	0.1%	1.3%	0.2%	3.5%	0.9%	




Fig 6

Table 1. Frequency of HLA-B\*14:01 versus HLA-B\*14:02 among viraemic controllers and non-controllers. ART-naïve chronically HIV-infected subjects were categorised as viraemic controllers (viral loads <2,000 copies/ml plasma) or non-controllers (viral loads >10,000 copies/ml plasma). Logistic regression was used to compute significance (p values), OR and 95%CI for the differences in frequency of HLA-B\*14 subtypes in controllers versus non-controllers, with adjusting by HLA-B\*57/27 expression. OR, odds ratio; CI, confidence interval; n/a, not applicable.

HLA-B*14+ (n=285)Ifrom 3,259 whites					HLA-B*14+¤(n=104)ªrom型1,745@blacks						
	Controllers,⊠ n	Non- controllers,? n		OR₫(95%2 Cl)	P2 value		Controllers, n	Non- controllers,⊠ n		OR[(95%][Cl)	P2 value
				Not⊠adju	sted					<b>Not</b> adjusted	
B*14:01	23	54	B*14:012	1.41 (0.80-	0.23	B*14:01	7	21	B*14:012	1.96፤(0.74-	0.18
B*14:02	78	130	B*14:02	2.47)	0.25	B*14:02	30	46	B*14:02	5.17)	
				Adjusted⊡fo B*57	-					Adjusted⊡for B*81	Ɓ*57,₽
B*14:01	23	54	B*14:012 vs	1.5410.86-	0.15	B*14:01	7	21	B*14:01? vs	1.523(0.56-	0.41
B*14:02	78	130	B*14:02	2.77)		B*14:02	30	46	B*14:02	4.13)	

**Table 2. HLA-B\*14:02 is significantly enriched among viraemic controllers.** Presence or absence of individual HLA-B alleles that have a frequency equal to or greater than that of HLA-B\*14:01 were tested by logistic regression with stepwise selection. OR, odds ratio; CI, confidence interval.

Wh	ites (n=	3,259)		Blacks (n=1,745)					
	Stepwise selection on HLA-B alleles that are of equal or greater frequency as B*14:01				allele	Stepwise selection on HI alleles that are of equal greater frequency as B*:			
	OR	95%CI	P value		OR	95%CI	P value		
B*57:01 vs others	0.25	0.20-0.32	2e-31	B*57:03 vs others	0.15	0.11-0.21	2e-29		
B*27:05 vs others	0.34	0.26-0.45	2e-15	B*81:01 vs others	0.20	0.12-0.33	1e-10		
B*52:01 vs others	0.40	0.25-0.63	7e-5	B*39:10 vs others	0.22	0.11-0.45	2e-5		
B*14:02 vs others	0.44	0.32-0.60	2e-7	B*57:01 vs others	0.41	0.19-0.91	3e-2		
B*13:02 vs others	0.47	0.33-0.67	3e-5	B*27:05 vs others	0.44	0.21-0.91	3e-2		
B*40:02 vs others	0.48	0.31-0.75	1e-3	B*14:02 vs others	0.54	0.32-0.90	2e-2		
B*08:01 vs others	1.66	1.28-2.13	1e-4	B*07:02 vs others	1.45	1.01-2.09	4e-2		
B*38:01 vs others	1.66	1.04-2.66	3e-2	B*53:01 vs others	1.51	1.12-2.03	7e-3		
B*40:01 vs others	1.76	1.24-2.50	2e-3	B*35:01 vs others	1.92	1.29-2.86	1e-3		
B*07:02 vs others	2.04	1.60-2.60	8e-9	B*15:10 vs others	2.27	1.33-3.89	3e-3		
				B*58:02 vs others	2.63	1.51-4.59	6e-4		
				B*45:01 vs others	4.10	2.36-7.13	6e=7		